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Abstract
Vascular calcification occurs during physiological aging and is clinically recognized as a
major risk factor for myocardial infarction, systolic hypertension, heart failure and
coronary insufficiency caused by loss of aortic recoil. Medial arterial calcification is an
active remodeling process that involves the deposition of bone-specific matrix in close
association with elastic fibers. Elastin, a major structural protein in the extracellular
matrix of arterial walls, provides elastic recoil to the arteries. Increasing evidence
suggests that vascular calcification share features with skeletal bone formation such as
bone matrix deposition and bone resorption. Bone morphogenetic proteins and bone cells
have been found in explanted atherosclerotic plaques. In bone, a homeostasis is
maintained by its two major cell types; osteoblasts and osteoclasts. Osteoblasts form new
bone matrix and osteoclasts, multinucleated giant cells which are derived from bone
marrow progenitor cells, are responsible for bone resorption.
Osteoclasts are derived from the monocyte/macrophage lineage of bone marrow
progenitor cells. Bone marrow progenitor cells differentiate into osteoclasts by cytokines
released by neighboring cells like activated T-lymphocytes, osteoblasts or bone marrow
stromal cells. Receptor activator of nuclear factor-kB ligand (RANKL) and 1α,
25(OH)2D3 (Vitamin D3) are examples of stimulates for osteoclast activation.
The objective of this project was to evaluate the use of osteoclasts differentiated from
bone marrow progenitor cells as a cell therapy to treat vascular elastin-specific
calcification.
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Chapter One
Introduction
According to the Centers for Disease Control, vascular disease is the leading cause of
death in the United States accounting for about 27% of deaths [1]. In many vascular
pathologies vascular calcification is observed. Arterial calcification leads to a hardening
of the artery and a narrowing of the lumen which affects blood flow. Vascular
calcification was once considered an end-stage passive crystallization process in which
mineral precipitates in extracellular fluids saturated with calcium and phosphates [2]-4].
However, studies over last 10 years have firmly established that arterial calcification is an
active regulated process similar to physiologic bone mineralization and associated with
the presence of bone growth factors and matrix proteins [3-4]. Elastin, a major structural
protein in the extracellular matrix of arterial walls, provides elastic recoil to the arteries.
Vascular calcification occurs in two distinct regions. Intimal atherosclerotic calcification
associated with plaques and medial elastin and vascular smooth muscle cells
calcification. Bone morphogenetic proteins and bone cells have been found in explanted
atherosclerotic plaques as well as in medial arterial calcification in close association with
elastic fibers. In bone, a homeostasis is maintained by its two major cell types;
osteoblasts and osteoclasts. Osteoblasts form new bone matrix and osteoclasts,
multinucleated giant cells which are derived from bone marrow progenitor cells, are
responsible for bone resorption. Bone marrow progenitor cells differentiate into
osteoclasts by cytokines released by neighboring cells like activated T-lymphocytes,
osteoblasts or bone marrow stromal cells. Receptor activator of nuclear factor-kB ligand
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(RANKL) [3] and 1α, 25(OH)2D3 (Vitamin D3) are examples of cells that stimulate
osteoclast activation. Osteoclasts have unique ability to resorb hydroxyapatite. As
vascular calcification resembles bone formation with active osteoblastic cells, the
objective of this project was to evaluate the use of osteoclasts differentiated from bone
marrow progenitor cells as a cell therapy to resorb vascular calcification.
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Chapter Two
Literature Review
According to the Centers for Disease Control, vascular disease is the leading cause of death in the
United States accounting for about 27% of deaths. Vascular disease has been the leading cause of
death for more than 20 years [1]. Arterial calcification leads to a hardening of the artery and a
narrowing of the lumen which affects blood flow. Vascular calcification was once considered an
end-stage passive crystallization process in which mineral precipitates in extracellular fluids
saturated with calcium and phosphates [2],[4],[5]. Recent findings have shown arterial
calcification to be a more active regulated process associated with the presence of bone growth
factors and matrix proteins [5] [4]. Osteoclasts are the only one cell type capable of resorbing
bone. This review will outline the mechanisms of vascular calcification, how it resembles bone
and how bone resorbing cells may be the key to reversing vascular calcification.
Outline
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1.1 Types of Arteries
1.1.1 Elastic
1.1.2 Muscular
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1.2.1 Tunica Intima
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1.4 Matrix Components of the Artery
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1.4.3 Other Components
2. Vascular Calcification
2.1 Intimal
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2.1.1.3 Bypass Surgery
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Normal Bone Structure and Composition
4.1 Types of Bone Mineralization
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4.3 Bone Homeostasis
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1. Normal Arterial Structure and Composition
The human vascular system is made up of several different arteries and veins. Native arteries are
comprised of a network of three distinct layers. Each layer has a distinct function and cells that
help facilitate in that. The artery also has several extra cellular matrix components that provide
strength and elasticity to the artery. Arteries can be categorized into to two major types.
1.1 Two Types of Arteries
There are two main types of arteries in the human body. The type of artery depends on its size
and function. The two types of arteries are elastic and muscular. They are very similar and have
one main distinguishing factor, the amount of elastin in the artery.
1.1.1 Elastic
Larger arteries that conduct blood from the heart are elastic arteries with a diameter around 2.5
centimeters. The aorta and its main branches like the carotid, subclavian and iliac arteries are
examples of these types of arteries. The arteries stretch in response to bolus of blood and
passively contract to regulate blood pressure. Elastic arteries are known for their multilayered
internal and external elastic lamellae surrounding the tunica media which protects the artery from
bursting during expansion and contraction. Elastic arteries have a media comprised of 40-70
elastic lamellae and very rich in smooth muscle cells and collagen.
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Figure 1. Diagram of an elastic artery.
(http://www.srmcheart.com/images/cvprofile%20.jpg )

1.1.2 Muscular
Muscular arteries are considered distributing arteries because they distribute blood to the body.
These arteries are smaller than elastic arteries and have a diameter ranging from 0.3 to 1.0
millimeters. The intimal layer is very similar in both elastic and muscular arteries, but they have
very different tunica media layers. The tunica media of muscular arteries has 3-40 smooth
muscle cell layers that dominate the elastic lamellae. The flow of blood is adjusted in these
arteries by the smooth muscle cell layers of the tunica media which respond to sympathetic nerve
stimulation.
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Figure 2. Diagram of a muscular artery.
(http://www.sci.sdsu.edu/class/bio590/pictures/lect5/artery-vein.jpeg)

1.2 Layers of the Artery
Native arteries are comprised of three main layers: tunica intima, tunica media and tunica
adventitia. Each layer has a different function and is made of different cells. The thickness of the
tunica layer increases as it gets farther from the blood stream.
1.2.1 Tunica Intima
The tunica intima is the innermost layer of the artery that actually comes in contact with the
blood. This layer consists of a layer of single endothelial cells and a very thin basal membrane of
connective tissue. The basal membrane serves to anchor the endothelial cells and provide
selective movement of nutrients to tissue.
1.2.2 Tunica Media
The tunica media layer is surrounded by the internal and external elastic lamellae. The internal
elastic lamellae separate the intima and media while the external lamellae divide the media and
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adventitia. The tunica media is composed of smooth muscle cells embedded in a network of
collagen and elastin. The smooth muscle cells in the media of elastic arteries are oriented
circumferentially into concentric layers separated by elastin sheets.
1.2.3 Tunica Adventitia
The tunica adventitia is the strong outermost covering of arteries. This layer consists of fibroblast
cells in a matrix of mostly collagen. The matrix of the tunica media contains sympathetic nerves
which regulate expansion and contraction of the arteries. This layer also contains a vaso vasorum
which is a network of vessels to provide nutrients to the outer layer of the artery which lacks
nutrient support from the intimal layer.
1.3 Cells of the Artery
The three most prominent cells in the artery are endothelial, smooth muscle and fibroblast cells.
Each cell is localized to a different layer of the artery and has its distinct role. Although each cell
has its own function, they all affect the other cells in the artery.
1.3.1 Endothelial Cells
Endothelial cells are arranged in a monolayer and line the lumen of all blood and lymphatic
vessels. These cells have a flat morphology and in culture are arranged in a cobblestone pattern,
but a spindle shape when exposed to flow and they align parallel to direction of shear flow.
Endothelial cells synthesize a protein-polysaccharide layer which attaches to the basement
membrane of the arteries known as the endothelium. The endothelium seals the vessel, but does
allow limited fluid transport. It also prevents blood from sticking to the luminal wall.

Endothelial cells also regulate the coagulation of blood by controlling circulating levels of
thrombin. Other functions of endothelial cells are to regulate platelet activity, fibrin recruitment
and vasodilatory responses. Depending on the circumstances endothelial cells can prevent or
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encourage platelet activity by secreting anti-platelet factors like nitric oxide and prostacyclin or
pro-platelet factors like von-willebrand factor. Fibrin clots are broken down by the secretion of
fibrinolysis by endothelial cells. These cells also regulate the action of smooth muscle cells by
producing vasodilators such as nitric oxide, prostacyclin and endothelin.
1.3.2 Smooth Muscle Cells
Smooth muscle cells (SMCs) are 30-40 microns long with fusiform or spindle-shaped
morphology. SMCs contain a single nucleus, mitochondria and thick and thin filaments like
myosin and actin. SMCs are organized in bundles which are oriented circumferentially and
surrounded by elastic fibers especially in elastic arteries. These cells are interconnected by gap
junctions which are specialized ports between cells that allow ion transport. Vascular SMCs
function in contraction and relaxation of arteries, synthesis and secretion of matrix, lipid
regulation and proliferation for repair and injury.
1.3.3 Fibroblasts
Fibroblasts in the tunica adventitia function in normal remodeling of the connective tissue.
Fibroblasts are contained in the adventitia and remain un-activated until an injury occurs. In
response to injury fibroblasts migrate to the neointima and secrete cytokines for vascular
remodeling [6-8].
1.4 Matrix Components of the Artery
The extracellular matrix (ECM) of arteries consists of a network of collagen, elastin,
proteoglycans and glycosaminoglycans in order of abundance. These matrix components give the
artery strength and support [9].
1.4.1 Collagen
Collagen is the most abundant protein in arteries by weight [10]. This protein is very stable and
has a very low turnover rate. The prominent types of collagen found in vasculature are collagen
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types I and III which form fibers by lateral aggregation and undergo lysyl oxidase-mediated
crosslinking. Collagen types IV and V are found in the basement membrane of arteries [11].
Type IV has great flexibility provided by helical interruptions while type V is associated with
types I and III and regulates collagen fiber formation giving tensile strength to the connective
tissue of the basement membrane. Collagen type VI is a microfibrillar collagen distributed only
in the aorta.
1.4.2 Elastin
Elastin is the extracellular matrix protein responsible for the elasticity of skin, arteries and lung
[12, 13]. Elastic fibers are assemblies that provide certain tissues with resilience, permitting
long-range deformability and passive recoil without energy input [14]. Many tissues require
elasticity for physiologic function [15]. Elastin fibers are present in the medial layer of the aorta
and elastic arteries in concentric fenestrated lamellae separated by smooth muscle cell layers [14].
These elastic fibers allow the vessels to maintain blood pressure by expansion during systole and
recoil during diastole [15].
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Figure 3. Cross-section of an artery showing orientation of elastin.
(Adapted from http://www.nature.com/nature/journal/v420/n6917/images/nature01323f4.0.jpg)

Elastin is an insoluble, hydrophobic and extensively cross-linked protein [12, 16]. It is
synthesized only by embryonic, rapidly growing tissues and cells derived from them [15]. Elastin
has a very low turnover in the body with a half-life of 70 years or more and can undergo 2 billion
stretch/relaxation cycles in the aortic arch during its lifetime [16]. Elastic fibers are designed to
function for a lifetime, but a few enzymes mainly matrix metalloproteinases and serine proteases
are able to cleave elastic fiber molecules [14]. Due to its low turnover rate, degradation of elastin
fibers leads to a number of diseases in the lungs and arteries. Destruction of lung elastin caused
by excessive elastase activity leads to emphysema [17]. Studies have shown one of the causes of
Marfan‟s syndrome to be a mutation in the elastin synthesis gene [18].
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Tropoelastin is the precursor to elastin. Tropoelastin is secreted into the extracellular space of
tissue and through the activity of the copper-requiring enzyme lysyl oxidase it becomes highly
crosslinked [15]. Elastin is constituted of polypeptide chains of tropoelastin monomers joined
together by cross-links called desomosine [12, 19]. The high degree of cross-linking of
tropoelastin, which takes place in the extracellular space is crucial for proper function of the
elastic fiber [15]. A critical step in the cross-linking pathway is the formation of a bifunctional
lysine cross-link intermediate, which then condenses with another bifunctional intermediate on a
second chain to form the tetrafunctional desmosine cross-links, which are exclusive to elastin [15]
[20].

Figure 4. Elastin structure in a relaxed and stretched state. Elastin molecules and
desmosine crosslinks are shown in stretched state. [21]

1.4.3 Other Components
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Glycosaminoglycans (GAGs) are amorphorus ground substance found in the ECM of vasculature.
It is made of unbranched long-chain polymers of repeating disaccharide units. GAGs are highly
negatively charged and hydrophilic because of the normally sulfated sugar residue of the
repeating disaccharide. Examples of GAGs are hyaluronic acid (which is the only non-sulfated
GAG), chondroitin sulfate, dermatan sulfate, heparin sulfate, heparin and keratin sulfate. GAGs
play an important role in tissue hydration by pulling large amounts of water into the ECM. They
are also involved in different roles in vasculature. For example, heparin is a potent anticoagulant
and others like heparin sulfate, dermatan sulfate and heparin bind to low and very low-density
lipoproteins and possibly affect plaque formation. GAGs are covalently bound to protein in the
form of proteoglycans. Proteoglycans contain a protein core with 50 or more attached GAG
chains. Proteoglycans are localized to the basement membrane of arteries and have a high
turnover rate [11].

Other components of the ECM of arteries which are found in lower abundance are fibronectin and
laminin [11]. Both are glycoproteins but laminin is localized to the basement membrane and
specifically attaches to endothelial cells and collagen type IV. Fibronectin is found in both tissue
and blood in a soluble form. In blood is participates in the wound healing cascade and promotes
platelet adhesion. In tissues it controls cell motility and differentiation.

2. Vascular Calcification
Vascular calcification was once considered an end-stage passive crystallization process in which
mineral precipitates in extracellular fluids saturated with calcium and phosphates [2, 4, 5, 22].
Arterial calcification leads to a hardening of the artery and a narrowing of the lumen which
affects blood flow. Recent findings have shown arterial calcification to be a more active
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regulated process associated with expression of growth factors, matrix proteins and bone-related
proteins [4, 5, 23]. There are two distinct types of arterial calcification: intimal calcification and
medial calcification.
2.1 Intimal Calcification
Intimal calcification is calcification associated with atherosclerotic plaque [24]. High cholesterol,
high blood pressure and smoking are all causes of atherosclerosis [25]. It occurs almost
exclusively in the intimal layer of the artery and is associated with lipid deposition, macrophage
accumulation and activation of vascular smooth muscle cells [26]. Intimal calcification is
hypothesized to begin with an injury to the intimal layer. An abundance of lipoproteins in the
blood stream can cause endothelial cell dysfunction. The lipoproteins can then migrate through
the intimal layer and causing an inflammatory response after becoming oxidized. This
inflammatory response induces an infiltration of macrophages to the sub-endothelial space which
absorb oxidized lipids and become foam cells forming a lipid core which hardens into a fibrous
plaque that can grow to impede the flow of blood through the intima. It can grow to the point of
total obstruction or break away to cause more damage upstream or possibly myocardial infarction
or stroke.
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Figure 5. Intimal calcification with advanced atherosclerotic plaque.
(http://www.nmh.org/nmh/adam/adamencyclopedia/graphics/images/en/18018.jpg)

2.1.1 Treatment Options
As atherosclerotic plaque grows and begins to impede the flow of blood an intervention is needed
to either re-open the artery lumen or re-route blood around the blockage. Treatments for intimal
calcification depend on the severity of the diseased artery, the location of the blockage as well as
other factors. Age and the overall health of the patient are also important factors that determine
the treatment used. The most common treatment options are balloon angioplasty, stent and
bypass surgery.
2.1.1.1 Balloon Angioplasty
Balloon angioplasty is the most commonly used treatments for less severely calcified arteries.
This procedure involves the use of a balloon on a catheter fed through the artery to the site of
calcification where the balloon is inflated to break up the plaque for lumen reopening. While this
procedure is minimally invasive and often used, there are drawbacks to it. Restenosis is a
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renarrowing of the lumen following the angioplasty procedure. Usually when the lumen is
opened during the angioplasty procedure, more damage is done to the diseased artery causing an
increased inflammatory response, proliferation of cells and resulting in a more severe
calcification than that which was originally treated.

Figure 6. Schematic shows how balloon angioplasty works to re-open lumen of a diseased
artery.
(http://www.keepingyouwell.com/CareAndServices/InterventionalRadiology/BlockedLegAr
teries.aspx)

2.1.1.2 Stent
The use of stents began in an attempt to prevent restenosis. A stent is a wire mesh placed over
the balloon which remains in the artery following balloon angioplasty. The stent is intended to
remain in the artery to keep the lumen open. Restenosis still occurs with the use of stents. More
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recently drug eluting stents have proven to be more effective in preventing the occurrence of
restenosis [27].

Figure 7. Stent remains in place after deployment of balloon to keep lumen open.
(http://www.lifespan.org/adam/graphics/images/en/19006.jpg)

2.1.1.3 Bypass Surgery
Bypass surgery is a procedure used to treat the most severely blocked arteries. It uses a synthetic
graft or autologous vein to redirect the flow of blood around the area obstructed by calcification.
Autologous grafts are more often used to bypass smaller arteries and synthetic grafts are more
useful for larger arteries. The use of synthetic grafts versus autologous grafts depends on the
availability of patients‟ veins or arteries for grafting.
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There are several limitations to this treatment. The availability of autologous grafts is the most
limiting factor. Also synthetic grafts are very prone to thrombosis and have issues with
anastomosis at the site of graft attachment.

These treatments are all used today even though each one has its own limitations and does not
completely eliminate the reoccurrence of calcification. Currently there is no treatment for
vascular calcification available that is cell based and completely reverses elastin calcification.

Figure 8. Bypass procedure uses a graft to direct blood flow away from the blockage.
(https://www.beaumonthospitals.com/files/health-library/images/em_2405.gif)

2.2 Medial Calcification
Medial arterial calcification is the mineral deposition in arteries and occurs independently of
atherosclerotic plaque [24]. Medial calcification, which is calcification of the medial layer, is
observed with particularly high frequency in disorders like end-stage renal disease and diabetes
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mellitus. Renal disease is often associated with diabetes [28, 29]. Patients with renal disease
experience increased vascular calcification due to elevated levels of serum calcium and phosphate
[30, 31]. Elevated calcium and phosphorus have led to increased vascular calcification in animal
studies as well as in vitro studies [28, 32]. Human aortic smooth muscle cells cultured in media
containing increased phosphate concentrations showed increased mineral deposition as well as
increased expression of osteogenic markers [33, 34]. Diabetes increases the occurrence of
vascular calcification in many ways including oxidized LDLs which can activate macrophages
and increased glucose concentrations which induce the generation of reactive oxygen species [28,
29, 35-37]. Although renal disease is often associated with diabetes and both diseases affect
vascular calcification in different ways, they both are associated with inflammation which greatly
affects vascular calcification. Both diabetes and chronic kidney disease have been recognized as
pro-inflammatory diseases and increase a particular cytokine which has pro-osteogenic
properties, tumor necrosis factor-alpha (TNF-α) [28]. In vitro calcifying vascular cells cultured
with TNF-α show an increased mineral deposition and alkaline phosphatase activity [38]. The
cells also undergo morphological changes from smooth muscle cells to osteoblast-like cells. A
patient with diabetes is likely to eventually have chronic renal disease and is very likely to have
increased vascular calcification compared to a patient without diabetes [28].

Another name for medial calcification is Monckeberg‟s sclerosis which affects arteries less prone
to develop atherosclerosis [24] and is typically associated with elastin calcification [26]. Medial
calcification involves a spontaneous phenotypic change of smooth muscle cells to an osteogenic
phenotype. It is also associated with the presence of bone morphogenic proteins (BMPs) which
are normally expressed exclusively by the bone forming cell, osteoblasts. Calcification and
degradation of elastin is also associated with the progression of medial calcification. The current
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treatments available are not for medial calcification. Elastin calcification is irreversible and does
not spontaneously regress.

Calcification

Figure 9. Monckeberg’s sclerosis only affects the medial layer of the artery.
(http://library.med.utah.edu/WebPath/COW/COW086.jpg)

3. Vascular Calcification Resembles Bone Mineralization
It was first reported by Virchow in 1863 that arterial calcification was very similar to that of bone
mineralization [39] and many recent studies have shown the presence of bone cells [40] and bone
proteins in calcified vascular matrix as well as fully formed bone tissue has also been found in
calcified human aortic valves [41]. Bone matrix proteins (BMPs) and matrix vesicles which give
rise to crystallization at low ionic concentrations of calcium and phosphate and both are present
in calcified valves and atherosclerotic lesions [41]. There are numerous publications which
examine the presence of bone markers in vascular calcification. I will summarize different
studies that have shown evidence of vascular calcification resembling bone mineralization.
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A study by Jeziorska concluded that the presence of osteoid, mineralized osteocytes, and
multinucleated osteoclasts in atherosclerotic plaque demonstrated bone formation [42].
Hydroxyapatite which is the inorganic phase of bone formation has been found in calcified
atherosclerotic plaques [4, 39, 40]. Both intimal and medial calcification show evidence of bone
mineralization by the presence of osteoblast transcription factor core binding factor-α1(CBFA-1)
[27] [43]. In particular, alkaline phosphatase (ALP), bone sialoprotein (BSP), matrix gla protein
(MGP), osteocalcin (OCN), osteonectin, osteopontin (OPN) and bone morphogenic protein-2
(BMP-2) have been found in calcified arteries [5, 44-46]. The presence of these bone proteins
lead to the hypothesis that vascular calcification is similar to bone mineralization because of their
importance in osteogenesis [45]. ALP increases the growth of hydroxyapatite while osteonectin
binds both collagen and hydroxyapatite [5]. OCN and BSP are produced by osteoblasts and are
associated with the early phases of bone formation [5, 47, 48]. MGP which is produced by both
osteoblasts and osteoclasts is known to bind calcium and has a high affinity for hydroxyapatite
[22]. BMP-2 has the full potential to initiate bone formation [5, 45].

In a 2001 study by Dhore, et al, they examined the presence of bone matrix regulatory proteins in
human atherosclerotic plaques taken from autopsy and vascular surgery [45]. Their study
revealed the presence of BMP-2 and BMP-4 in fibrocalcific plaques. Osteonectin was also
upregulated in atherosclerotic lesions. BSP, an early marker for bone formation [47], was only
detected in more mild, early atherosclerotic plaque but not detectable in the fully formed calcified
atherosclerotic lesions. OPG was upregulated in the fibrocalcific plaque signifying the blockage
of osteoclast activity.
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Dhore also examined non-diseased tissue and found five bone matrix proteins (MGP, OC, BSP,
BMP-4 and OPG), but not BMP-2 and OPN which are key proteins for late bone formation.
These findings suggest that bone regulatory proteins are present throughout the entire
calcification process of atherosclerotic arteries. These studies have examined clinically calcified
arteries and found many bone markers present.

Laboratory experiments have also shown evidence of the similarity between vascular calcification
and bone mineralization. Knockout mice studies have also added to argument that bone and
arteries calcify in the same manner. By silencing key regulatory bone proteins mice express
severe vascular calcification. MGP has some effects on osteoclast function and its knockout mice
have extensive calcification of aorta including aortic valves [4, 5, 49, 50] and die within about 2
months [45]. MGP deficient mice also show extensive medial arterial calcium deposition. MGP
is also expressed in normal arteries to suggest an inhibitory effect [40]. Mice lacking Smad6, the
gene known to inhibit BMP-2 signaling, exhibit extensive arterial calcification [40].

In vitro studies have also shown results for the affirmative argument that vascular calcification is
like bone. Calcifying vascular cells (CVCs) express BMP-2, OCN, OPN, ALP, osteonectin and
collagen type I under certain stimuli in culture [40, 50, 51]. Bovine aortic smooth muscle cells
(BASMCs) lose their SMC phenotype in culture with phosphate and express ALP, OCN and
OPN to appear osteoblast-like [4, 49]. Ultrastructural analysis also confirms the presence of
hydroxyapatite, calcifying collagen and nodular calcification similar to that observed in calcified
atherosclerotic plaques in vivo.
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BMP-2 has also been shown to decrease the expression of SMC markers in vitro after growth
arrest is induced [43]. Once cell arrest is induced by BMP-2 SMCs lose their native phenotype
and begin to express an osteoblastic profile. Vascular SMCs of MGP-deficient mice undergo
chondrogenic and osteogenic differentiation when treated with BMP-2 [43]. A study by Lee, et al
showed the time dependent expression of osteogenic markers like Cbfa-1 and alkaline
phosphatase in close proximity of calcified elastin in a rat subdermal model suggesting that it
resembles medial vascular calcification [26].

It has been established that vascular calcification is similar to bone through clinical examination,
knockout mice and in vitro studies. In order to further examine the link between vascular
calcification and bone, we should have a more clear understanding of bone and how it functions
normally.

4. Normal Bone Structure and Composition
Bone is a dynamic tissue which functions in protection of internal organs, provides mechanical
support for the body, acts as a lever for muscle action, site for hematopoiesis, calcium
homeostasis and a store of phosphate, magnesium, potassium and bicarbonate [52, 53]. Calcified
bone contains about 25% organic matrix, 5% water and 70% inorganic material (hydroxyapatite).
4.1 Types of Bone Mineralization
There are two mechanisms of bone formation, intramembranous bone formation and
endochondral ossification. Intramembranous bone formation involves messenchymal cells
differentiating directly into osteoblasts which then deposit mineral to create bony structures
without cartilage formation [54]. This type of bone formation is found during flat bone formation
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(eg. skull development). If the differentiation of mesenchymal cells proceeds via chondrocytes to
form cartilaginous templates of future bone, the process is termed endochondral ossification [54].
The cartilage template is replaced by invading osteoblasts which allow ossification of the
structure, which is the common mechanism for mineralization in long bones.
4.2 Bone Cells
There are three distinctly different cell types in bone: osteoblasts, osteocytes and osteoclasts.
Osteoblasts are the bone-forming cells. They lay down the extracellular matrix and regulate its
mineralization [53, 54]. Osteoblasts may become trapped in their own calcified matrix, changing
their phenotype and developing into osteocytes [54]. Osteocytes are the most abundant cell type
in bone and create a network of intercellular communication with bone-lining cells (inactive
osteoblasts). Osteoclasts are the large multinucleated giant bone-resorbing cells [55, 56].
Osteoclastic bone resorption initially involves mineral dissolution followed by degradation of the
organic phase [53]. Bone is continuously being resorbed and rebuilt. This remodeling process is
maintained by a homeostasis between osteoblasts and osteoclasts. When a team of osteoclasts dig
a trench across the surface of a trabecula, it is then refilled by a team of osteoblasts [57] [53] [58].
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Osteoclast

Osteoblasts

Figure 10. Schematic shows the biological function of osteoclasts and osteoblasts.
(www.glaciermedicaled.com/ bone/bonesc3p5.html)

The main function of osteoclasts is to degrade and resorb mineralized bone matrix. Osteoclasts
are the only cells capable of dissolving hydroxyapatite. The osteoclasts migrate to the resorption
site and form a sealing zone under the cell. The resorption cycle begins with dissolution of
crystalline hydroxyapatite and organic matrix rich in collagen. Integrins are proposed to play an
important role in this resorption. Integrin αvβ3 in particular has a high affinity for denatured
collagen type I and has been found in the ruffled border of osteoclasts as well as the plasma
membrane and various intracellular vacuoles [59]. Horton showed that inhibition of integrin αvβ3
was effective in inhibiting bone resorption [60]. Hydroxyapatite crystals are dissolved by targeted
secretion of acids such as hydrochloric acid (HCl) through the ruffled border into the resorption
lacuna [61].
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The resorption lacuna is an extracellular space between the ruffled border membrane and bone
matrix which is sealed from the surrounding environment by a sealing zone. Proton pumps at the
ruffled border and intracellular vacuoles maintain an acidic environment in the resorption lacuna.
Carbonic anhydrase II is essential for the function of the proton pumps [62].

Figure 11. Diagram shows the mechanism of osteoclastic bone resorption.
(http://a248.e.akamai.net/7/248/430/20040414150433/www.merckfrosst.ca/e/research/r_d/fut
ure_challenges/images/bone_diagram.gif)

After the bone mineral phase is solubilized, the organic matrix is further degraded by proteolytic
enzymes. Two classes of proteolytic enzymes are involved in the degradation process lysosomal
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cysteine proteinases and matrix metalloproteinases, in particular Cathepsin K and MMP-9 or
gelatinase B, respectively [63, 64]. Cathepsin K has been shown to degrade collagen type I [65].
Once degradation is complete, the byproducts are removed from the resorption lacuna through a
transcytotic vesicular pathway of the ruffled border to the functional secretory domain where they
are liberated into the extracellular space. Tartrate Resitant Acid Phosphatase (TRAP) [66] is
localized in these transcytotic vesicles of resorbing osteoclasts [3].

Osteoclasts are similar to macrophages because they are derived from the same lineage[67]. Salo
reported that osteoclasts and macrophages have similar transport pathways [68]. The monocyte
lineage of hematopoeitic stem cells from the bone marrow can differentiate to osteoclasts,
macrophages or dendritic cells depending on its cytokine exposure early in the differentiation
process [69, 70] [71-73]. A promyeloid precursor will differentiate into an osteoclast if it is
exposed to Receptor activator of nuclear factor-kB ligand (RANKL) [61, 74-76] [71]. RANK
[77], its ligand (RANKL) and osteoprotegrin (OPG) are all members of the tumor necrosis factor
(TNF) ligand and receptor signaling family [77, 78]. RANKL is a trans-membrane protein of
osteoblasts, marrow stromal cells, T-lymphocytes and other ostoeoblastic lineage cells [77, 79]
[80] [81] [82]. RANKL also exists in a soluble form (sRANKL) once cleaved from the cell
surface or secreted by T cells [79, 83, 84]. RANKL binds to RANK, which is expressed on preosteoclasts. The binding is essential for all aspects of osteoclast function such as differentiation,
maturation, fusion, survival and activity [77, 79]. RANKL expression in the osteoblast lineage is
baseline until upregulated by 1,25-dihydroxyvitamin D3 and dexamethosone [79, 85-87]. These
osteolytic factors also inhibit OPG expression. OPG in known to inhibit osteoclastogenesis and it
does so by inhibiting the binding of RANKL to RANK [79, 83]. OPG is produced as a soluble
decoy of RANKL [77]. Bone marrow stromal cells and osteoblasts produce membrane bound
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and soluble RANKL to stimulate osteoclast differentiate. This known phenomenon leads us to
believe that osteoclasts and osteoblasts are coupled, but little is known about the exact
mechanism of their coupling and communication. OPG is a soluble factor produced by some
cells that strongly inhibits osteoclast formation in vitro and in vivo. OPG prevents binding of
RANKL to its receptor RANK [88].

Figure 12. The RANK/RANKL/OPG system is essential in osteoclast differentiation and
inhibition [43].

Bone marrow is the source of osteoclast precursors. Hematopoiesis, regulation and production of
mature blood cells from primitive stem cells, occurs primarily in the bone marrow[15, 89, 90].
The bone marrow is also a rich source of stem cells. It maintains undifferentiated hematopoietic
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stem cells and supports differentiation of erythroid, myeloid and lymphoid lineages [15, 90]. In
addition to hematopoietic stem cells, the bone marrow also contains marrow stromal cells or
mesenchymal stem cells.

Mesenchymal cells are multipotent and able to differentiate into connective tissue lineages [15,
90] including fibroblasts, osteoblasts, adipocytes, osteocytes, myocytes and neural cells [91, 92].
These mesenchymal stem cells have also been found to provide growth factors and matrix
proteins through cell-to-cell interaction that play a role in maintaining hematopoietic cells [15,
90, 91].

The hematopoietic cells can be divided into two major groups: myeloid and lymphoid [89, 93].
The myeloid lineages include erythrocytes (red blood cells), monocyte lineage- derived cells
(macrophages, osteoclasts, and dendritic cells), granulocytes (neutrophils, eosinophils, basophils
and mast cells) and platelets. The lymphoid lineage includes thymus-derived T-lymphocytes,
BM-derived B-lymphocytes and natural killer (NK) cells.
4.3 Bone Homeostasis
Bone is an active living tissue constantly remodeling itself. Normal remodeling allows for the
formation of new bone by osteoblasts after the removal of old bone by osteoclasts [94].
Remodeling is also important for the function on bone as a source of calcium and phosphorus.
This process is particularly important in childhood because it allows bones to grow, but this
process continues throughout life. While remodeling is important is normal bone function,
abnormalities in this process is the primary cause of disease in bone. Two major forms of bone
diseases are osteoporosis and osteopetrosis which are both directly related to an imbalance in
remodeling.
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4.4 Bone Diseases
Osteoporosis is the most common bone disease. The imbalance in the remodeling process by an
abundance of osteoclast function results in a loss of bone mass and a fragile skeleton. It is related
to an increased porosity of the bone caused by increased osteoclast activity. Patients suffering
with osteoporosis have reduced bone mass and a high incidence of fracture. Osteoporosis can be
localized to a particular region or affect the entire skeleton. It is mainly a disease of the elderly
especially post menopausal women. Osteoporosis is usually brought on by a deficiency in
calcium, vitamin D and estrogen. Estrogen deficiency causes an increase in RANKL which is
directly related to osteoclast function [94].

Osteopetrosis is a condition in which bones are too dense because of a failure of osteoclast
formation or function. This is a rare hereditary disease [94]. These dense bones do not remodel
well in response to mechanical forces or microdamage and are actually weaker and subject to
fracture. In this abnormality of the remodeling process, the trabecular bone invades the marrow
space and does not allow enough space for normal formation of blood cells [94]. The balance of
osteoblasts to osteoclasts is the cause of most bone diseases, which may also be the link between
vascular calcification and bone mineralization.

5. Link between Vascular Calcification and Bone Mineralization

It has been established that vascular calcification and bone mineralization are very similar, but
can they be regulated by the same mechanisms? Osteoclasts are the cells which resorb bone and
an overexpression of them can lead to excessive bone loss or osteoporosis. In bone, homeostasis
is maintained through the RANK/RANKL/OPG system [77, 95, 96].
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RANKL (then called OPGL) was first discovered as a replacement for stromal cells and vitamin
D3 in osteoclast cell cultures in 1998 by Lacey and associates[83, 97, 98]. They discovered that it
binds to hematopoeitic progenitors of osteoclast lineage to form and activate osteoclasts in vitro
along with M-CSF [99]. Before this discovery mature osteoclasts were formed in vitro from bone
marrow and spleen cells with vitamin D3 and stromal cells [83]. M-CSF (also known as CSF-1)
is important to osteoclast maturation because it regulates survival, proliferation and
differentiation of mononuclear cells [99]. Intravenous [83] injections of M-CSF to mice caused
circulating monocyte counts to increase from 3-30% [99].

All of the RANK/RANKL/OPG system has been found in vascular cells. OPG deficient mice
exhibit osteoporosis and medial calcification of aorta and renal arteries [77]. Osteoporosis and
vascular calcification frequently occur together and share the same risk factors [100]. RANKL is
expressed in the calcified arteries of OPG (-/-) mice, but undetected in normal, noncalcified
arteries [79, 84, 101]. OPG is highly expressed in normal arteries [102]. The calcification of
arteries in OPG knockout mouse occurs without fat deposition as seen in atherosclerosis patients
[101]. Therapeutic injections of a high dose of recombinant OPG to OPG deficient mice did not
affect the incidence of arterial calcification [101]. Significantly lower levels of sRANKL were
observed in patients with severe arterial calcification [77, 100].

Even though calcified arteries are expressing markers of bone formation, there are also markers
for bone resorption suggesting that there may be a natural attempt by the body to reverse the bone
mineralization occurring in the arteries. RANKL is essential for osteoclast survival and it has
been expressed in a number of vascular tissues [40]. Another osteoclast marker, Cathepsin K, has
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been found in atherosclerotic plaques [40]. Normal arteries may also produce MGP to prevent
osteogenic mineralization as suggested by the expression MGP in normal arteries as compared to
atherosclerotic arteries [22]. One particular study examined the presence of RANKL and OPG in
explanted atherosclerotic, monckeberg sclerotic and normal arteries [77]. The results show that
RANKL was expressed diffusely throughout the diseased arteries, but not in the normal arteries.
OPG was also expressed in close proximity to the site of calcification in the diseased arteries and
diffusely in the normal arteries

While there are several similarities to vascular calcification and bone, there is one major
component that is not. There is no elastin in bone. Bone markers and cells may have been found
in calcified arteries but to date there are no findings of elastin proteins in bone. There is also
evidence of potential bone resorption in calcified arteries as previously described by the presence
of osteoclast-specific markers, RANKL and Cathepsin K, being found in calcified arteries. Can
bone resorption mechanisms be used to reverse arterial calcification? Several reviews have also
pondered this question [50, 103-105]. A review by Massy thoroughly examined the similarities
between vascular calcification and bone and hypothesized that osteoclast-like cells could be the
missing link [105]. It is unclear at this time if a local balance of osteoblastic phenotypes to
osteoclastic phenotypes in calcifying arteries could be tilted to osteoclastic resorption of
calcification so to restore native arteries there are two ways that this can be achieved; local
delivery of mature osteoclasts through a gel delivery system close to vascular calcification and
recruitment of osteoclast progenitors to the site of calcification. Cell based therapies have been
used to treat a number of different diseases and may be the answer to vascular calcification. I
will outline a brief history of cell therapy, give examples of how it‟s being used today and go
over its potential as a treatment for vascular calcification.
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6. Cell Therapy
Human bone marrow transplants (BMT) were first used in the 19th century sporadically, but the
modern era began in 1957 by French and Yugoslav physicians [106, 107]. The physicians used
human BMT to treat workers involved in a nuclear reaction accident. This same treatment was
also used again three decades later in the Russian Chernobyl accident. BMT is now a world wide
treatment for selected malignant and non-malignant disorders including leukemia, Hodgkin‟s
lymphoma, cancer (breast, lung and skin), sickle cell and osteopetrosis [106]. BMT can be both
autologous and allogenic.

There are a few complications associated with patients receiving BMT , most often involving
infection [107]. One particular complication of allogenic BMT unrelated to infection is graftversus-host-disease (GVHD) [108]. GVHD is when the transfer of tissues between individuals
results in recognition and rejection of the transplant in a host-versus-graft reaction. This
phenomena was first noted when irradiated mice were infused with normal spleen and although
the mice recovered from radiation injury and marrow aplasia they subsequently died with a
secondary disease consisting of diarrhea, weight loss, skin changes and liver abnormalities [108].
In 1966 Billingham outlined the requirements for development of GVHD to be: 1. the graft
contains immune competent cells and host appears foreign to graft and 2. the host cannot mount a
sufficient immune reaction to graft [107, 108]. A treatment for GVHD consists of
immunosuppressants post transplant.

Even though BMT has been used for several years many advances have been made to take this
therapy into the future. GVHD probability has been drastically decreased with the introduction of
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T-cell depletion of donor marrow [109]. Another treatment for GVHD is the use of more targeted
cells with immunoaffinity “positive” selection of CD34+ cells [110]. Human stem/progenitor
cells have the highest expression of CD34. Precursors of hematopoietic stromal cells, osteoclasts
and endothelial cells express CD34. One draw back to this treatment is that CD34 expression is
only 1.5% of aspirated bone marrow and monocytes comprise 6-8% of circulating white blood
cells [106, 110].

Since the first use of BMT, there have been many advances for cell therapy as well as the use of
other stem cells to treat various diseases. Stem cell therapy is currently involved in 2442 clinical
trials [111]. Adult marrow is a potential source of stem cells to treat a wide of degenerative
diseases and damaged tissues like in osteoarthritis, diabetes mellitus, Parkinson‟s disease,
ischemic heart disease and retinal degeneration [112-114]. The use of adult stem cells could also
be used to treat diseases like stress urinary incontinence for which there has only been the
undesirable treatment of a pelvic sling [115]. Cell based therapies have been used for cartilage
and tendon repair [116].

Symptoms of Parkinson‟s disease and retinal degeneration have been alleviated by the use of
microencapsulated retinal pigment epithelial cells [27] [117] [27]. The cells are maintained in a
non-dividing state and secrete neutrophic factors to treat both diseases. The cells also produce
dopamine and neutrophic support of the basal ganglia to assist in management of Parkinson‟s
disease. Neural stem cells have also been used to treat Parkinson‟s disease as well as spinal cord
injuries [118]. Cell based therapies are showing promise in fetal surgery to treat spina bifida
using neural stem cells [119].
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Cell therapy has also been proven as a great treatment in the cardiovascular field. Stem cell use
has great potential in treating hearts damaged by myocardial infarction [120]. Transplantation of
autologous CD31+ and CD34+ cells induced neovascularization and improved ventricular
function after myocardial infarction in pig and rat models [121]. Endothelial progenitor cells
isolated from the bone marrow have also been used to achieve cell-based neovascularization in
damaged myocardium [122].

Cell therapy has proven to be effective for many diseases including those in the cardiovascular
field. Transplanted autologous cells have survived and induced improvement in myocardial
infarction and we are proposing a similar treatment. We plan to transplant autologous osteoclasts
which have been matured in vitro and also recruit osteoclast progenitors to the site of
calcification. We hypothesize that the osteoclasts would resorb the elastin calcification.

7. Epilogue
In this literature review, it has been established that vascular calcification is a disease that
threatens Americans and the treatments available are not effective in reversing its causes.
Vascular calcification resembles bone with the presence of bone cells which express BMPs as
well as other important osteogenic markers. It is also established that osteoclasts are the only
cells capable to resorb bone hydroxyapatite. The RANK/RANKL/OPG system could be the link
to reverse elastin calcification. Cell therapy is also a potential treatment for several diseases and
has proven effective in a few models.

Below is schematic by Doherty from a publication in which they outlined why osteoclasts may
the answer to treat vascular calcification. In the box labeled bone, it details the mechanism in
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which an osteoclast matures and resorbs bone and the box labeled atherosclerotic plaque is
depicting the question can osteoclasts do the same to resorb the mineral phase found in vascular
calcification. Our research hypothesis is based on the same principle. We hypothesize that a sitespecific delivery of osteoclasts may have the potential to limit or reverse elastin calcification. We
also plan to examine the effect of RANKL as a recruiter of osteoclasts to the site of calcification.

Figure 13. Pictorial depiction of our research hypothesis [50].
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Chapter Three
Projection Rationale
Hypothesis
Vascular calcification occurs during physiological aging and is clinically recognized as a major
risk factor for myocardial infarction, systolic hypertension, heart failure and coronary
insufficiency caused by loss of aortic recoil. Medial arterial calcification is an active remodeling
process that involves the deposition of bone-like mineral in close association with elastic fibers.
Elastin, a major structural protein in the extracellular matrix of arterial walls, provides elastic
recoil to the arteries. Increasing evidence suggests that vascular calcification share features with
skeletal bone formation such as presences of bone-specific proteins, osteoblast like cells, bone
matrix deposition. Bone morphogenetic proteins (BMPs) and bone cells (osteoblast and
osteoclasts) have been found in explanted atherosclerotic plaques. In bone, a homeostasis is
maintained by its two major cell types; osteoblasts and osteoclasts. Osteoblasts form new bone
matrix and osteoclasts, multinucleated giant cells which are derived from bone marrow progenitor
cells, are responsible for bone resorption. As active bone remodeling and mineral deposition is
observed in arteries, we wanted to test whether osteoclast cell based therapy could be used to
resorb vascular elastin specific calcification. We would use a two pronged approach. Initially we
will attempt to site specifically deliver autologous osteoclasts which have been matured in vitro to
the calcification site. We will also attempt to recruit native osteoclast progenitors to the site of
calcification. We hypothesize that a site-specific delivery of osteoclasts may have the potential to
limit or reverse elastin calcification.
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Specific Aims

Aim I: Evaluation of media supplements and their effect on osteoclast differentiation and
elastin demineralization in vitro
Studies were performed to determine the most effective media supplements for osteoclast
differentiation. Bone marrow progenitor cells (BMPCs) were incubated with different media
supplements intended to induce differentiation into osteoclasts. We also examined the effect of
these differentiated cells on elastin demineralization in vitro.

Aim II: Evaluation of mature osteoclasts (OCs) derived from BMPCs in vitro and their
effect on elastin demineralization
In the previous aim we determined the best media supplementation for differentiation of BMPCs
into OCs and we showed that during differentiation these cells can demineralize calcified elastin.
For this aim we examined if OCs have the same effect if previously differentiated to maturity.
BMPCs were differentiated into mature OCs by incubation with Vitamin D3/Retinioc Acid media
supplementation. Mature osteoclasts derived from bone marrow progenitor cells were used to
demineralize calcified elastin.

Aim III: Evaluation of osteoclasts derived from bone marrow progenitor cells to limit
elastin calcification in vivo
In vitro studies shown that OCs differentiated from BMPCs were effective at demineralizing
calcified elastin during and post differentiation. Next, we wanted to examine whether local
delivery of OCs can inhibit elastin calcification in vivo. Mature osteoclasts derived from BMPCs
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were incorporated into collagen gels and implanted subdermally close to purified porcine elastin
implants. The progression of calcification in presence of OCs was studied.

Aim IV: Evaluation of site-specific delivery of osteoclasts to reverse elastin calcification in
vivo
Previous aims examined OCs ability to demineralize calcified elastin in vitro and their ability to
limit the progression of elastin calcification in vivo. In a clinical settings, arteries would be
calcified before therapy begins. Thus, we wanted to examine whether OCs can limit or resorb
already established elastin calcification in vivo.

We first induced elastin calcification by

subdermally implanting purified elastin forone week. We reopened the implant site and then
delivered mature OCs directly to the site for elastin demineralization.

Aim V: Evaluation of RANKL as a recruiter of native osteoclasts to demineralize calcified
elastin in vivo
One approach would be to recruit native monocytic cells to the site and mature them to osteoclast
like cells rather than isolating cells from bone marrow and then delivering them to the site. Thus,
for this aim we attempted to recruit native OCs to the site of elastin calcification. In a clinical
setting, it would require less surgical manipulation to recruit native cells than transplanting cells
differentiated in vitro. Elastin was subdermally implanted and allowed to calcify for one week.
RANKL and OPG (agents that are known to attract osteoclast like cells) were then delivered
directly to the implant site to recruit and mature monocyte cells to OCs for elastin
demineralization.
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Aim VI: Evaluation of osteoclasts to reverse arterial elastin-specific calcification in an
abdominal aortic injury model
This aim was most clinically relevant approach to our hypothesis. We used a rat aortic injury
model where native artery was allowed to calcify in the medial layer similar to what is seen in
human disease of arteriosclerosis. For this study calcium chloride was applied periadventitially
for fifteen minutes to the abdominal aorta (infra renal) of Sprague Dawley rats to cause medial
calcification of the aorta. Mature osteoclasts were then delivered periadventitially to the aorta to
reverse elastin calcification.
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Chapter Four
Evaluation of Media Supplements and their Effect on Osteoclast Differentiation and
Elastin Demineralization in vitro
Introduction
We hypothesized that mature allogenic osteoclasts (OCs) derived from bone marrow
progenitor cells (BMPCs) can be delivered to the site of calcification to regress vascular
calcification. There are two different methods used to differentiate OCs from BMPCs.
Vitamin D3 with retinoic acid has been used for a long time for OC differentiation [123].
More recently in literature Receptor activator of nuclear factor-kB ligand (RANKL) has
been extensively used for OC differentiation since its discovery in 1998 [83]. We wanted
to test which method would give us a higher population of osteoclast cells.
Materials and Methods
Progenitor Cell Isolation
Bone Marrow Progenitor Cells (BMPCs) were isolated from adult Sprague-Dawley rats
by flushing the marrow space of femurs and tibias with warm Iscove‟s media with 10%
fetal bovine serum (FBS) and 1% antibiotic/antimycotic (Ab/Am) (Sigma, St. Louis,
MO). The flushed cells are filtered through a 40 µm cell strainer (BD, Franklin Lakes,
NJ) and centrifuged. The cells are resuspended in Iscove‟s culture media (Iscove‟s media
with 20% FBS and 1% Ab/Am) and layered onto Ficoll-Paque gradients (Amersham
Biosciences, Piscataway, NJ) then centrifuged. The mononuclear cell layer was isolated
from the gradients and cultured in Iscove‟s culture media.
Differentiation of BMPCs to OCs

52

RANKL Concentration
To examine the effect of different concentrations of RANKL on the differentiation of bone
marrow progenitors to osteoclasts, human RANKL (BioVision, Mountain View, CA) was added
to the culture media at three different concentrations; 5 ng/ml, 10 ng/ml and 20 ng/ml. In these
conditions, bone marrow progenitor cells differentiate into mature osteoclasts after approximately
fourteen days.
Vitamin D3+Retinoic Acid vs RANKL
To examine the effect of Vitamin D3+Retinoic Acid vs RANKL on the differentiation of bone
marrow progenitors to osteoclasts, all-trans retinoic acid (Sigma, St. Louis, MO) and 1,25Dihydroxyvitamin D3 12 (Sigma, St. Louis, MO) added in 10-6M concentrations to culture media
and 10 ng/ml RANKL separately. In these conditions, bone marrow progenitor cells differentiate
into mature osteoclasts after approximately fourteen days.

Flow Cytometry

Differentiated cells were tripsinized and washed twice in DLB buffer (DPBS with 1%
bovine serum albumin). Cells were then fixed in 2% paraformaldehyde for 30 minutes.
Cells were permeabilized with 0.1% Triton for 5 minutes followed by a wash in staining
buffer. Cells were stained with 0.5uM calcein (Invitrogen, Carlsbad, CA) for 15 minutes
at 37⁰C in the dark. After a wash in staining buffer (DPBS with 2% bovine serum
albumin and 0.05% sodium azide), the cells were stained with Cathepsin K primary
antibody (Abcam, Cambridge, MA) for one hour in the dark followed by three washes in
staining buffer. Cells were then stained with secondary antibody of Alexa Fluor 594
(InVitrogen, Carlsbad, CA) for 15 minutes in the dark, followed by a wash in staining
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buffer. We used the Agilent 2100 bioanalyzer to perform microchip flow cytometry
analysis and the Agilent Cell Fluorescence kit. (Agilent Technologies, Santa Clara, CA).
Cell Phenotype Verification
Differentiated OCs were stained for tartrate-resistant acid phosphatase (TRAP), which is
a stain specific for OCs, using a TRAP kit following manufacturer‟s instructions (Sigma,
St. Louis, MO).
Bioactivity of Osteoclasts
BMPCs (5x104 cells/gel) were seeded onto hydroxyapatite coated discs (BD, Franklin
Lakes, NJ), which simulate bone, and cultured with RANKL and Vitamin D3/retinoic
acid media supplementation separately for fourteen days. After culture, media was
removed and then discs were rinsed with deionized water three times. Discs containing
cells were bleached by adding 1 mL of bleach solution (6% NaOCl, 5% NaCl) with
agitation at 37°C. Discs were again washed three times with deionized water then
allowed to air dry. The discs were stained for calcium using the von Kossa staining
procedure to reveal any resorption pits (observed microscopically) formed by the OCs.
Purification of Porcine Elastin
Elastin was purified from fresh porcine aorta tissue obtained from a local abattoir
following a procedure originally described by Partridge [124]. Porcine aortas were
transported from the local abattoir in sterile 0.9% NaCl on ice. The tissue was cut into 2
mm strips and washed several times in distilled water. The tissue was then shredded and
washed in 0.9% NaCl until the content of soluble proteins was undetectable by BCA
assay (Pierce, Rockford, IL). Collagen denaturation was achieved by numerous cycles of
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autoclaving. The tissue was then dried to remove any remaining lipids with ethanol and
diethyl ether yielding pure elastin. The pure elastin was stored at 4°C.
Subdermal Elastin Implantation
Previously purified porcine elastin was hydrated 1-2 hours prior to surgery in sterile
Phosphate buffered saline (PBS) without calcium and magnesium (Mediatech, Manassas,
VA). Juvenile male Sprague-Dawley rats (Harlan Laboratories, Indianapolis, IN)
weighing ~30 g were placed under general anesthesia (2% isoflurane) then two incisions
were made on the back above the shoulder blades (left and right side) as shown in Figure
followed by the formation of subdermal pockets by blunt dissection. The hydrated elastin
~30 mg was packed into sterile 1cc syringes with the tips removed. The elastin was
injected into the subdermal pockets and the incisions were closed with staples. The
animals were humanely euthanized using CO2 asphyxiation at day seven.

Figure 14. Location of subdermal elastin implants.
Calcified Elastin Incorporation into Collagen Gel
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Explanted calcified elastin was homogenized in 100% ethanol then the ethanol was
evaporated using a continuous stream of sterile nitrogen gas. A collagen solution
previously prepared with eight parts PureCol® (Advanced BioMatrix, San Diego, CA),
one part 10X Phosphate Buffered Saline (PBS) and one part 0.1 M Sodium Hydroxide
(NaOH) in a 50 mL centrifuge tube on ice. The mixture was vortexed vigorously and pH
adjusted to 6.5-7.0 with 0.5 M Hydrochloric Acid (HCl). Homogenized elastin was
added to the collagen mixture at a concentration of 2.5mg/ml then 0.5 ml of
elastin/collagen mixture was added to well plates and allowed to solidify sterilely at 37°C
for ~30 minutes. Once solid, differentiated OCs (5x104 cells/gel) were seeded onto the
gels and cultured for fourteen days.
Calcium Analysis
The media was removed from the gels which were then washed three times with
deionized water and frozen at -80°C and lyophilized. The dried samples were hydrolyzed
in 6 N HCl in a boiling water bath. The hydrochloric acid was evaporated using a
continuous stream of nitrogen gas then reconstituted in 0.01 N HCl. Calcium content was
measured using atomic absorption spectrophotometry (Aanalyst 200, Perkin-Elmer,
Norwalk, CT).
Statistical Analysis
Data are reported as means ± SEM. Student‟s t-test was used to determine differences
between groups. Data are termed statistically significant when p<0.05.
Results
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BMPCs cultured for 14 days were 43%, 41%, and 39% differentiated to OCs at 10, 15,
and 20 ng/ml RANKL respectively (Figure 15). As no significant difference was
observed for the different concentrations, the lowest concentration (10 ng/ml) of RANKL
was used for further experiments.
A

B

C

D

A: BMPC Only B: 10 ng/ml RANKL C: 15 ng/ml RANKL D: 20 ng/ml RANKL

Figure 15. Characterization of OCs differentiated from BMPCs by incubation in varying
concentrations of RANKL by flow cytometry.
Next, the two methods for differentiation were compared by culturing BMPCs in Vitamin
D3 and retinoic acid (10-6M) and RANKL (10 ng/ml) separately for 14 days and the
amount of differentiation was measured using flow cytometry. BMPCs incubated with
Vitamin D3 with retinoic acid differentiated into OCs more than those incubated in
RANKL. Even though the same amount of cells were seeded Vitamin D3 incubation
expressed more than 2X more positive cells than RANKL (Figure 16).
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A

B

C

A: BMPC-C B: BMPC-D3R C: BMPC-RANKL

Figure 16. BMPCs incubated with Vitamin D3 retinoic acid (B) were 2X more positive
for the Cathepsin K antibody than those differentiated with RANKL (C).
Cells cultured with both methods were positively identified as OCs by tartrate resistant
acid phosphatase (TRAP) staining as evidence by the reddish-brown stain (Figure 17).
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BMPC-D3R

BMPC-RANKL

10X

Figure 17. BMPCs differentiated into OCs with Vitamin D3 and retinoic acid (top) and
RANKL (bottom) were all positively TRAP stained.
For validation of mineral-resorptive abilities, BMPCs were seeded onto hydroxyapatite
discs, which simulate the mineral phase of bone and allow visualization of resorptive
activity. After 14 days in culture with both differentiation methods, resorption pits were
clearly visible. Both methods for obtaining osteoclasts from rat bone marrow were
effective at inducing hydroxyapatite dissolution by the cells. Vitamin D3 incubation did
cause more resorption pits than RANKL (Figure 18).
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A

B

C

D
A: Disc w/o cells B: BMPC-C
C: BMPC-RANKL D: BMPC-D3R

Figure 18. BMPCs cultured with and without (B) media supplements are capable of
forming resorption pits but Vitamin D3 with retinoic acid (D) caused more cells to form
resorption pits than RANKL (C).
BMPCs without any differentiation were not able to remove calcium from the calcified
elastin. Osteoclasts differentiated by Vitamin D3 with retinoic acid and RANKL both
significantly induced demineralization of calcified elastin (p<0.05) (Figure 20). Elastin
content was analyzed by desmosine analysis performed by radio immunoassay. There
was no reduction in desmosine content during demineralization by either method of
differentiation clearly indicating that elastin was not significantly degraded during
demineralization process (Figure 20).

60

Figure 20. BMPCs cultured in Vitamin D3 with retinoic acid and RANKL significantly
reduced calcium content (top) in calcified elastin but did not reduce elastin content
(bottom) in the process (n=4).
Discussion
In order to prove our hypothesis that mature allogenic osteoclasts (OCs) derived from
bone marrow progenitor cells (BMPCs) can be delivered to the site of calcification to
regress vascular calcification, we had to test the most common methods for OC
differentiation found in literature: Vitamin D3 with retinoic acid and RANKL
(Thavarajah, 1991; Lacey,1988). Osteoclasts are of hematopoietic origin and their
precursors can be differentiated into mature OCs in vitro under specific conditions.
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The percentage of cells differentiated into mature OCs was measured using flow
cytometry. Vitamin D3 and RANKL as media supplements are both effective in
differentiating BMPCs into OCs as shown by flow cytometry results, however,
Vitamin D3 was more effective and provided more OCs than RANKL. Cells
differentiated by both methods were stained TRAP positive by revealing a reddishbrown stain further verifying the differentiation into mature osteoclasts (Yasuda,
1998). The bioactivity of the cells during differentiation was analyzed by the ability
of the cells to form resorption pits on hydroxyapatite coated discs. The coating on the
discs simulate the mineral matrix of bone and since OCs are the only bone resorbing
cells, their formation of resorption pits indicate successful differentiation into mature
OCs (Contractor, 2005). OCs differentiated with Vitamin D3 created more resorption
pits than those differentiated in RANKL.
Given the similarities of vascular calcification and bone, we next examined the ability
of OCs to resorb vascular calcification. Osteoclasts differentiated from BMPCs using
both Vitamin D3 and RANKL as media supplements were effective in demineralizing
calcified elastin, while undifferentiated cells were ineffective clearly showing that
prior differentiation to OCs is required for cells to remove mineral from elastin.
Although the use of OCs as a treatment for vascular calcification is quite novel one of
the side effects could be that osteoclasts will degrade extracellular matrix of
vasculature while resorbing the mineral. OCs are known to secrete ECM degrading
enzymes such as MMPS and cathepsin that can degrade elastin. We evaluated if
resoprtion of elastincalcification by OCs would cause any damage to elastin by
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desmosine assay. Others have shown that desmosine assay is a marker of elastin
degradation (lower the desmosine content, the higher is the degradation) (Starcher,
1977). Our desmosine data showed no alteration after OCs incubation suggesting that
during demineralization process, the elastin was not degraded. This data is
encouraging as shows that we can use OCs cell therapy for demineralization without
causing too much damage to the existing vascular ECM. We clearly need to show that
collagen, another important ECM component, is also not degraded by OCs.
The comparison of the two differentiation methods for OCs is not well documented in
the literature. Ours was first of its kind of side-by-side comparison of these two
methods. RANKL is the newer, more widely used method for OC differentiation but
as our results have shown the older method of Vitamin D3 with retinoic acid is more
effective at OC differentiation. The examination of both methods and their effect on
demineralization of calcified elastin showed no difference between the methods.
Thus, both methods create OCs that can resorb mineral from elastin.
In conclusion, Vitamin D3 and RANKL as media supplements are both effective in
differentiating BMPCs into OCs, however, Vitamin D3 was more effective and
provided more OCs than RANKL. Osteoclasts differentiated from BMPCs using both
Vitamin D3 and RANKL as media supplements were effective in demineralizing
calcified elastin and during the demineralization process, the elastin was not degraded
as assessed by desmosine analysis.
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Chapter Five
Evaluation of Mature Osteoclasts Derived from Bone Marrow Progenitor Cells in
vitro and Their Effect on Elastin Demineralization
Introduction
As shown in the previous chapter, we examined the two most common differentiation
methods for OC differentiation from BMPCs [83, 123] and showed that BMPCs could
be differentiated into OCs when cultured with Vitamin D3 and RANKL media
supplements and effectively formed resorption pits as well as demineralized calcified
elastin during differentiation. Vitamin D3 appeared to be more effective than RANKL for
differentiation of BMPCs into OCs, therefore; Vitamin D3 was our chosen method for
osteoclast differentiation for further studies. For those studies, differentiating media was
present when BMPCs were contacted with elastin and we allowed them to differentiate
during demineralization. For this aim, we decided to see if
OCs would have the same effectiveness in demineralization when differentiated to
maturity first. This will be more clinically relevant as bone marrow cells can be obtained
from the patients and matured to OCs in vitro prior to their delivery to the pathologic
calcification site.

Materials and Methods
Osteoclast Isolation
Bone Marrow Progenitor Cells (BMPCs) were isolated from adult Sprague-Dawley rats
by flushing the marrow space of femurs and tibias with warm Iscove‟s media with 10%
fetal bovine serum (FBS) and 1% antibiotic/antimycotic (Ab/Am) (Sigma, St. Louis,
MO). The flushed cells are filtered through a 40 µm cell strainer (BD, Franklin Lakes,
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NJ) and centrifuged. The cells were resuspended in Iscove‟s culture media (Iscove‟s
media with 20% FBS and 1% Ab/Am) and layered onto Ficoll-Paque gradients
(Amersham Biosciences, Piscataway, NJ) then centrifuged. The mononuclear cell layer
was isolated from the gradients and cultured in Osteoclast Culture Media (Iscove‟s
culture media with all-trans retinoic acid and dihydroxyvitamin D3 (Sigma, St. Louis,
MO) added in 10-6M concentrations). Mature osteoclasts (OCs) were differentiated from
BMPCs by culturing them with defined media for 14 days. Differentiated cells attached
to the flask while undifferentiated cells remain unattached and floated off.
Histology
Mature OCs were seeded onto sterile glass slides and cultured in osteoclast culture media
overnight for sufficient adherence. The media was removed after overnight culture and
the slides were washed in warm PBS to remove any un-adhered cells and other debris.
The OCs were then stained following the standard Hematoxylin and Eosin (H&E)
staining procedure. OCs were also stained for tartrate-resistant acid phosphatase
(TRAP), which is a stain specific for OCs, using a TRAP kit (Sigma, St. Louis, MO).
Bioactivity of Osteoclasts and Demineralization of Calcified Elastin
The experiments were performed the same as in the previous chapter only the cells were
differentiated to maturity before being seeded.
Results
Osteoclast morphology was determined by H&E staining and phenotype was determined
by TRAP staining (Figure 21). Large cells with multiple nuclei were found in H&E
staining indicative of osteoclasts.

TRAP gives reddish-brown stain specific to
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osteoclasts. Several multi nucleated cells were found to stain for TRAP also indicating
osteoclasts.

Figure 21. Morphology and Phenotype verification of OCs differentiated by VitaminD3
with retinoic acid by H&E staining (A&B) and TRAP staining (C&D).
Biological function of the differentiated cells was verified by their ability to form
resorption pits on hydroxyapatite discs. The hydroxyapatite coated discs simulate bone
and the OCs form pits by resorbing the hydroxyapatite layer of the discs (Figure 22).
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Figure 22. Mature OCs differentiated using VitaminD3 with retinoic acid form early
resorption pits by day 7 (B) and fully formed pits by day 14 (C&D). No cells were seeded
on disc in A.
Calcium analysis showed that previously matured OCs were able to demineralize
calcified elastin (Figure 23). Media from the culture study was also analyzed for calcium
levels and results showed that demineralization of calcified elastin by OCs increased the
calcium levels in the media.
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Figure 23. OCs have the ability to demineralize calcified elastin (n=4).
Discussion
BMPCs were differentiated in two weeks into mature OCs using vitamin D3/retinoic acid
supplementation before use in any experiments. The differentiated cells demonstrated all
of the morphologic and phenotypic aspects of OCs with the multiple nuclei shown by
H&E staining and positive reddish brown stain by TRAP staining [125]. The mature
OCs were also biologically active and formed resorption pits on hydroxyapatite discs
further verifying the mature differentiation into OCs [126].
It is well documented that bone and vascular calcification are quite similar and given that
OCs are the only bone resorbing cells, we evaluated if OCs would be effective at
demineralizing calcified elastin if differentiated to maturity first. The use of OCs as a
treatment for vascular calcification is a very new concept. In the previous chapter we
showed that during differentiation OCs were able to demineralize calcified elastin and for
this aim we explored the effectiveness of mature OCs. We did see similar results for the
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OCs that were in the differentiation phase and those that were maturely differentiated.
The mature OCs act the same as OC precursors because even though they are mature,
they are not activated. OCs are not activated until in the presence of mineralization. This
is also confirmed by the formation of resorption pits by BMPCs with any media
supplementation. Literature also shows that OCs produce factors for activation
themselves [80]. The maturely differentiated cells were effective at demineralizing
calcified elastin. In conclusion, we have shown that OCs are able to resorb calcification
during differentiation and after maturity.
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Chapter Six
Evaluation of Osteoclasts Derived from Bone Marrow Progenitor Cells to Limit
Elastin Calcification in vivo
Introduction
Previous chapters have focused on the in vitro evaluation of our hypothesis that a sitespecific delivery of OCs will demineralize calcified vascular elastin. We have shown that
BMPCs can be differentiated into OCs using Vitamin D3 with retinoic acid media
supplementation. We have also shown that these cells are effective at demineralizing
calcified elastin in vitro.
The calcified elastin used for the previous in vitro studies was calcified using a subdermal
calcification model which uses juvenile rats. In vitro experiments shown promising
results, however, in such experiments OCs were directly placed over calcified elastin. It
is much more complex when OCs need to resorb mineral in vivo. They have to survive at
the site and not altered by inflammatory and remodeling responses. For this aim we
examined the effectiveness of OCs to limit the progression of elastin calcification in vivo.
Material and Methods
This experiment uses several methods that are the same as those used in previous
chapters. Osteoclasts were isolated then cultured to maturity and porcine aortic elastin
was purified the same as before.
Osteoclast Labeling and Collagen Gel Encapsulation
The morning of surgery mature OCs were labeled using CellTrace™ Far Red DDAO-SE
(Molecular Probes, Carlsbad, CA). Once labeled, the cells were added to a collagen

72

solution previously prepared with eight parts PureCol® (Advanced BioMatrix, San
Diego, CA), one part 10X Phosphate Buffered Saline (PBS) and one part 0.1 M Sodium
Hydroxide (NaOH) in a 50 mL centrifuge tube on ice. The mixture was vortexed
vigorously and pH adjusted to 6.5-7.0 with 0.5 M Hydrochloric Acid (HCl). Previously
purified porcine aortic elastin was then added to cell/collagen mixture. The
elastin/cell/collagen mixture was taken up into 1 ml syringes (with tips removed for
easier implantation) with a cell concentration of 2.1x104 cells/gel with 30 mg elastin/gel
and allowed to solidify sterilely at 37°C for ~30 minutes. Control groups include elastin
in collagen gel (30mg/gel) and OCs in collagen gel (2.1x104 cells/gel). Once solid, the
collagen gels were sterilely transferred to the surgery suite for implantation.
Subdermal Implantation
Juvenile male Sprague-Dawley rats (Harlan Laboratories, Indianapolis, IN) weighing ~30
g were placed under general anesthesia (2% isoflurane) then two incisions were made on
the back above the shoulder blades (left and right side) as shown in Figure 24 followed
by the formation of subdermal pockets by blunt dissection. The gels (n=3) were injected
into the subdermal pockets and the incisions were closed with staples. The animals were
humanely euthanized using CO2 asphyxiation at days one, three and seven.
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Figure 24. Location of subdermal elastin implants.
Histology
Following euthanasia, some of the subdermal explants were removed for fluorescent
imaging and others were embedded in OCT (Sakura Finetek, Torrance, CA) and frozen
on dry ice. The frozen tissue was later sectioned and stained following the standard
Hematoxylin and Eosin (H&E) staining procedure. The other samples were coverslipped with DAPI mounting media (Molecular Probes, Carlsbad, CA) to fluorescently
image the implanted cells.
RNA Isolation and Gene Analysis
Total RNA was isolated from tissue explants using the RNeasy Fibrous Kit (Qiagen,
Valencia, CA). Quality and quantity of RNA were evaluated on an Agilent 2100
Bioanalyzer using the RNA 6000 Nano kit (Agilent Technologies Inc., Foster City, CA).
Five hundred nanograms of total RNA was then reverse transcribed using RetroScript Kit
(Ambion, Austin, TX). The cDNA sample was further amplified using a Rotorgene 3000
thermal cycler (Corbett Research, Mortlake, NSW, Australia) and QuantiTect SYBR
Green PCR kit (Qiagen,Valencia, CA), which allows real-time quantity detection of PCR
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products. Target-specific primers were synthesized by Integrated DNA Technologies Inc.
(Coralville, IA). Minus RT and minus cDNA samples were included in each set of
samples. Each sample was normalized to the expression of ß-2 microglobulin (2-MG) as
a housekeeping gene and compared to control samples (elastin in collagen gel only) using
the 2-ΔΔCT method.
Calcium and Desmosine Analysis
The capsule was removed from the day seven explanted samples which were then frozen
at -80°C and lyophilized. The dried samples (~10-15 mg) were hydrolyzed in 6 N HCl in
a boiling water bath. The hydrochloric acid was evaporated using a continuous stream of
nitrogen gas then reconstituted in 0.01 N HCl. Calcium content was measured using
atomic absorption spectrophotometry (Aanalyst 200, Perkin-Elmer, Norwalk, CT). The
same hydrolysates were analyzed for desmosine content using radioimmunoassay [127].
Statistical Analysis
Data are reported as means ± SEM. Student‟s t-test was used to determine differences
between groups. Data are termed statistically significant when p<0.05.
Results
Unprocessed tissue samples were analyzed microscopically for the presence of OCs.
Histological analysis of the unprocessed tissue confirmed the presence of the
fluorescently labeled OCs (red) at days one and three (Figure 25 A&B respectively).
H&E staining showed the presence of OCs at day three in the sectioned tissue samples
(Figure 25 C&D). The presence of OCs could not be confirmed at day seven by
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histological analysis. It is not clear what happened to the cells between days three and
seven, it is possible that they did not survive.

A

B

C

D

Figure 25. Fluorescently labeled OCs (red) were present in the subdermal implant at days
one (A) and three (B). H&E staining also shows the presence of OCs (denoted by arrows)
at day three (C&D).
The subdermal implants were also examined for gene expression of Cathepsin K, an OC
specific protease, to further examine why OCs were not visible by histological analysis at
day seven. Explants from days three and seven were analyzed for cathepsin K and the
presence of OCs could only be confirmed in day three explants by an 2.5 fold overexpression of Cathepsin K (Figure 26). Gene analysis further confirmed histological data
as no overexpression of Cathepsin K was observed at day seven clearly showing
functional osteoclast cells were absent at the site.
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Figure 26. Cathepsin K over-expression at day three verifying the presence of OCs (n=3).
Interestingly, calcium analysis of day seven samples revealed a 56% lower elastin
calcification in the presence of OCs (Figure 27). Collagen gel with incorporated OCs did
not calcify.
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Figure 27. OCs limit the progression of elastin calcification (n=3).
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Thus, OCs were effective at limiting the progression of elastin calcification. Next we
wanted to verify that elastin was not degraded by the OCs. Elastin integrity was
examined by desmosine analysis. Desmosine analysis is frequently used to study elastin
integrity [127]. Desmosine analyses showed no alteration in desmosine levels suggesting
that OCs did not degrade elastin while limiting the progression of elastin calcification
(Figure 28).
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Figure 28. Elastin was not degraded by OCs during implantation (n=3).
Discussion
Our in vitro studies showed that OCs have the ability to resorb calcified elastin, but here
we examined if they would be able to limit the progression of elastin calcification in vivo.
Our research group has used this accelerated calcification model previously to investigate
the mechanisms of elastin calcification and have shown that calcium deposits are
exclusively related with the elastin fibers [128]. We have also shown that this model
shares many similarities with bone formation, including the presence of osteoblastic cells
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[26]. To the best of our knowledge, this is the first research attempt to use cell therapy for
limitation of elastin calcification. Since OCs are the only cells capable of resorbing cells
[129], this approach seems reasonable.
Calcium analysis of the implants after seven days confirmed our hypothesis that OCs
would limit the progression of elastin calcification. OCs limited elastin calcification by
56%. We also examined the integrity of elastin after implantation with OCs to verify no
degradation of elastin by OCs. Elastin integrity was analyzed by desmosine analysis
[127] and showed no elastin degradation by OCs.
We also wanted to confirm the presence of OCs during implantation. The OCs could be
identified in elastin implants after three days via fluorescence microscopy, histology and
PCR indicating that live, functional OCs were present. The presence of OCs could not be
confirmed at day seven indicating a limited life span of OCs after implantation [130]. The
data suggests that early presence of OCs up to 3 days prevented or delayed initial
calcification of elastin. Although cells were absent after few days (either died or cleared
from the area) they were clearly functional in first few days and did limit progression of
elastin calcification. It may be possible that by day seven remodeling response ensues
with fibroblast migration and collagen deposition and delivered OCs are removed further
away from the elastin implant.
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Chapter Seven
Evaluation of Site-Specific Delivery of Osteoclasts to Reverse Elastin Calcification in
vivo
Introduction
Thus far we have demonstrated that BMPCs can be differentiated into OCs using vitamin
D3 with retinoic acid media supplementation. We have also shown that these mature OCs
have the ability to demineralize calcified elastin in vitro as well as limit the progression
of elastin calcification in vivo [131]. In a clinical setting elastin would already be
calcified before treatment would be applied. The reversal of elastin calcification is more
clinically relevant. Therefore, we attempted to reverse elastin calcification by a sitespecific delivery of OCs.
Our approach to reverse elastin calcification was a three step effort. All studies began
with purified elastin being subdermally implanted and allowed to calcify for seven days
then at day seven a cell therapy treatment was delivered to the site of calcification. First,
we injected a cell suspension directly into the implant site. Our next effort at treatment
was reopening the subdermal pocket and implanting a collagen gel with encapsulated
cells next to the implant. Finally, we reopened the subdermal pocket and implanted
collagen/alginate beads with cells encapsulated as an attempt to reverse elastin
calcification.
Materials and Methods
Osteoclasts were isolated and differentiated with Vitamin D3 as previously described. For
elastin calcification studies, porcine aortic elastin was purified and subdermally
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implanted the same as described in chapter one. The elastin was allowed to calcify for
seven days before cell therapy treatment.
Cell Therapy Treatment:
Cell Injection
The morning of surgery, mature OCs, BMPCs and rat skin fibroblasts were suspended in
sterile PBS (1x105 cells/0.5 mL) and sterilely transferred to the surgery suite for
injections. Control group includes saline injections (0.5mL/injection). For injections, the
animals from the previous procedure were held by an assistant while the injections were
delivered directly to the implant site. The animals were humanely euthanized using CO2
asphyxiation seven days following application of the treatment.
Osteoclast Labeling and Collagen Gel Encapsulation
The morning of surgery mature OCs were labeled using CellTrace™ Far Red DDAO-SE
(Molecular Probes, Carlsbad, CA). Once labeled, the cells were added to a collagen
solution previously prepared with eight parts PureCol® (Advanced BioMatrix, San
Diego, CA), one part 10X Phosphate Buffered Saline (PBS) and one part 0.1 M Sodium
Hydroxide (NaOH) in a 50 mL centrifuge tube on ice. The mixture was vortexed
vigorously and pH adjusted to 6.5-7.0 with 0.5 M Hydrochloric Acid (HCl). The
cell/collagen mixture was taken up into 1 ml syringes (with tips removed for easier
implantation) with a cell concentration of 5x105cells/gel and allowed to solidify sterilely
at 37°C for ~30 minutes. Control groups include collagen only. Once solid, the collagen
gels with encapsulated DDAO-labeled OCs were sterilely transferred to the surgery suite
for implantation.
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The animals from the previous surgery were placed under general anesthesia (2%
isoflurane) then two incisions were made on the back above the shoulder blades (left and
right side) followed by the formation of subdermal pockets by blunt dissection to expose
the previously implanted elastin. Once the previous implant was located, the gels were
placed next to the elastin implant and the site was closed staples. The animals were
humanely euthanized using CO2 asphyxiation seven days following application of the
treatment.
Collagen/Alginate Bead Preparation
Beads were prepared by mixing 0.1% w/v sodium alginate (Sigma, St. Louis, MO ) with
0.1% w/v bovine tendon collagen (EPC,). This mixture was taken up into a syringe and
placed into a syringe pump (Medfusion Injector, Medex Inc, Yellowknife, NT). The
solution was then pushed through a 21G needle and dropped into a gently stirring

2%

w/v calcium chloride (Sigma, St. Louis, MO). Once the mixture was completely
dispensed, the beads were allowed to stir for one hour to ensure complete crosslinking
and were then washed three times in DI water.
Cell Encapsulation in Collagen/Alginate Beads and Viability
Rat skin fibroblasts were fluorescently labeled with CellTrace™ Far Red DDAO-SE
(Molecular Probes, Carlsbad, CA) then centrifuged and the cell pellet was added to the
alginate/collagen mixture then the beads were prepared the same as described above but
the entire process was performed steriley. After the washing step, the beads with cells
encapsulated were placed into well plates and cultured for seven days in DMEM with
10% FBS and 1% Ab/Am. At day seven, media was removed from the cultures and MTS
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(Promega, Madison, WI) Cell Viability assay was run on the media then beads were
removed from the culture dish and picogreen DNA assay (Invitrogen, Carlsbad, CA) was
performed on cells attached to the culture dish to determine if there was any cell
proliferation from the beads.
Osteoclast Labeling and Collagen/Alginate Bead Encapsulation
The morning of surgery mature OCs were labeled using CellTrace™ Far Red DDAO-SE
(Molecular Probes, Carlsbad, CA). OCs were encapsulated into the collagen/alginate
beads the same as described above and transferred to the surgical suite for implantation.
The animals from the previous surgery were placed under general anesthesia (2%
isoflurane) then two incisions were made on the back above the shoulder blades (left and
right side) followed by the formation of subdermal pockets by blunt dissection to expose
the previously implanted elastin. Once the previous implant was located, the beads were
placed next to the elastin implant and the site was closed staples. The animals were
humanely euthanized using CO2 asphyxiation seven days following application of the
treatment.
Calcium and Desmosine Analysis
The capsule was removed from the explanted samples which were then frozen at -80°C
and lyophilized. The dried samples (~10-15 mg) were hydrolyzed in 6 N HCl in a
boiling water bath. The hydrochloric acid was evaporated using a continuous stream of
nitrogen gas then reconstituted in 0.01 N HCl. Calcium content was measured using
atomic absorption spectrophotometry (Aanalyst 200, Perkin-Elmer, Norwalk, CT). The
same hydrolysates were analyzed for desmosine content using radioimmunoassay [127].
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RNA Isolation and Gene Analysis
Total RNA was isolated from tissue explants using the RNeasy Fibrous Kit (Qiagen,
Valencia, CA). Quality and quantity of RNA were evaluated on an Agilent 2100
Bioanalyzer using the RNA 6000 Nano kit (Agilent Technologies Inc., Foster City, CA).
Five hundred nanograms of total RNA was then reverse transcribed using RetroScript Kit
(Ambion, Austin, TX). The cDNA sample was further amplified using a Rotorgene 3000
thermal cycler (Corbett Research, Mortlake, NSW, Australia) and QuantiTect SYBR
Green PCR kit (Qiagen,Valencia, CA), which allows real-time quantity detection of PCR
products. Target-specific primers were synthesized by Integrated DNA Technologies Inc.
(Coralville, IA). Minus RT and minus cDNA samples were included in each set of
samples. Each sample was normalized to the expression of ß-2 microglobulin (2-MG) as
a housekeeping gene and compared to control samples (elastin only) using the 2-ΔΔCT
method.

Results
Seven days after initial delivery of OCs, elastin was explanted and amount of calcium
deposited was assayed with atomic absorption spectrophotometry. Calcium analysis
revealed no significant reduction in calcification of elastin in the presence of any cell type
injected (Figure 29). Cellular injections proved ineffective for reversal of elastin
calcification.
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Figure 29. Cells injected at the site of elastin calcification were not effective in reducing
calcification (n=4).
This is possibly because the cells did not remain at the implant site for enough time to
demineralize the calcified elastin. Gene analysis showed that Cathepsin K levels were
two fold higher in all groups including fibroblast group as compared to elastin implant
control (Figure 30). Clearly, just delivering cells to the site was enough to increase Cat-K
expression. At seven days, early markers of bone-specific gene, Cbfa-1, remained
unchanged while alkaline phosphatase, which is expressed during calcification process
was significantly higher in the OC injection group. ALP levels encompass more than just
bone; it refers to the general production of phosphatase. OCs use phosphatase in the
process of demineralization and this could be the cause for increased ALP gene
expression in OC group.
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Figure 30. Gene analysis of the implants show that cell injections had no effect to reduce
bone-specific genes (n=4).
As injections of cells suspended in saline were ineffective in reversing elastin
calcification probably due to the difficulty of staying in place at the implant site, we then
decided that some sort of gel delivery system was needed to deliver the cells. Thus, we
used collagen gels to deliver the cells to the site of calcification. Again, calcium analysis
of elastin in the collagen gel treatment showed no reduction in elastin calcification in the
presence of OCs (Figure 31).

87

90
80
ug Ca/mg dry tissue

70
60
50
40
30
20
10
0
Day 7 Ctrl

Day 14 Ctrl

Collagen

OC

Figure 31. OCs delivered by collagen gel were ineffective for reversal of elastin
calcification (n=4).
Gene analysis showed slightly reduced Cathepsin K levels in the OC group as compared
to the day fourteen control. Cbfa-1 gene was over-expressed in the OC group but ALP
levels were reduced.
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Figure 32. Gene analysis results vary but the variance was not enough to affect
calcification.
Our final attempt to reverse elastin calcification using cell therapy was with
collagen/alginate beads. In vitro studies were performed first to optimize bead
preparation and cell encapsulation. Beads were made with varying ratios of collagen and
alginate and the beads averaged 0.2 cm in size. The beads with equal parts collagen and
alginate (1:1) were not homogenous in size (Figure 33).

Figure 33. Beads made of varying collagen/alginate concentrations.
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The beads made with 7:3 collagen/alginate were weak and mushy. Increasing
concentrations of alginate improved stiffness and handling properties of the beads. The
beads with 3:7 collagen/alginate mixtures showed better handling properties and
therefore they were used for further studies.
Cell encapsulation was successful and fluorescently labeled cells were observed within
the collagen/alginate beads (Figure 34).

Figure 34. Cells (red) were successfully encapsulated into collagen/alginate beads.
The cells remained viable during encapsulation as confirmed by the MTS cell viability
assay (Figure 35). While the cells were viable within the bead, picogreen DNA assay
showed that they did not migrate from thee bead and attach to the culture dish (Figure
36).
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Figure 35. Cells encapsulated within collagen/alginate beads are viable and metabolically
active (n=6).

40

*

ug/ml DNA Conc

35
30
25
20
15
10

*

5
0
Cells Alone

Cells on Beads

Figure 36. Encapsulated cells did not proliferate from the beads and attach to the culture
dish (n=6).
In vivo analysis of the beads as a delivery vehicle for OCs to reverse elastin calcification
showed that the collagen/alginate beads kept the cells localized to one specific area
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(Figure 37). Prior to euthanasia the animals were imaged using Lumazone imaging
technology to visualize the position of the fluorescently labeled cells.

Figure 37. Imaging of the fluorescently labeled OCs seven days after implantation
showed that the collagen/alginate beads kept the cells localized during implantation.
Calcium analysis of the implants did not reveal any difference in calcification in the
presence of the beads containing OCs (Figure 38).
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Figure 38. Delivery of OCs by collagen/alginate beads was not effective for reversal of
elastin calcification (n=4).
Gene analysis of the implants showed higher expression of Cathepsin K confirming that
the collagen/alginate beads kept OCs at the implant site while OCs injected as a
suspension in saline was not effective at keeping cells at the implant site (Figure 39). The
bone protein expression found was intriguing. When OCs were injected in saline bone
related genes were significantly over-expressed. Both Cbfa-1 and ALP levels were two
fold that of the control, but in the group where the OCs were delivered in the beads, the
levels remained unchanged as compared to the elastin only control.
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Figure 39. Gene analysis of the implants confirm that collagen/alginate beads kept OCs at
the implant site (n=4).
Discussion
It has been very well documented that vascular calcification is very similar to that of
bone mineralization (Jeziorska, 2001; Bobryshev, 1995; Bostrom, 1995). The accelerated
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calcification model used for this study has been previously used by our research group to
investigate fundamental mechanisms of elastin calcification [128]. Our group has also
shown that the elastin calcification observed in this model shares many similarities with
bone formation, including the presence of osteoblastic cells that are positive for Cbfa-1
surrounding the calcified elastin [26]. The focus of this aim was to use OCs, the only
bone resorbing cells [129], to reverse elastin calcification. To our knowledge this was the
first attempt to use OCs as a cell therapy treatment to reverse elastin calcification.
Cell therapy is a treatment that has been used for numerous other diseases. More recently
cell therapy has been proven as a great treatment in the cardiovascular field. Stem cell use
has also shown great potential in treating hearts damaged by myocardial infarction [120].
Transplantation of autologous CD31+ and CD34+ cells induced neovascularization and
improved ventricular function after myocardial infarction in pig and rat models (Melo,
2004). Endothelial progenitor cells isolated from the bone marrow have also been used to
achieve cell-based neovascularization in damaged myocardium (Melo, 2004). The recent
findings in literature using bone marrow derived stem cells to treat cardiovascular
diseases supports our hypothesis to use bone marrow derived OCs to treat vascular
elastin-specific calcification.
Our attempts to reverse elastin calcification through cell therapy using OCs did not show
results that we had hoped. When cells were suspended in saline, the cells did not remain
at the site of calcification and were ineffective at reversing calcification. We tried to
deliver the cells using a delivery vehicle as opposed injecting them in a suspension. OCs
were incorporated into a collagen gel and delivered to the site of calcification. Previously
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we have shown collagen gels to be a great delivery vehicle for OCs [131]. However the
collagen gel didn‟t keep the cells localized long enough for the cells to have an effect on
calcification. Our last attempt using a delivery vehicle was with the use of
collagen/alginate beads. We showed that we could encapsulate the cells into the beads
and the cells remained viable during encapsulation [132]. The beads were very effective
at keeping the cells localized to a specific area but the cells did not proliferate and
migrate out from the beads to reverse elastin calcification. We used collagen/alginate
beads with the intention of alginate degraded slower than collagen alone to ensure the
cells would be kept in place and the delivery vehicle degrade slowly for the cells to
remain at the implant site longer and be able to reverse calcification. The
collagen/alginate beads did degrade slower than the collagen gel alone but unfortunately
too slowly. The beads could still be found at the implant site at the time of euthanasia.
Literature has shown the use of alginate to long-term cell entrapment and immobilization
as opposed to a short-term delivery vehicle followed by in vivo degradation [84, 132].
The bone protein data was intriguing. When osteoclast cells were delivered in saline
because of their presence bone protein levels were also higher. It is possible that body is
trying to regulate mineral formation and resorbtion to a certain degree. In bone, OCs
regulate behavior of osteoblasts and vice versa. It is thus possible that presence of OCs
allowed increased bone cell type phenotype from nearby cells. When OCs were
encapsulated in beads, they remained entrapped and did not cause this response in the
nearby cells. Overall, it is clear that it is difficult to tilt the balance to osteoclastogenesis
from osteoblastogenesis when the calcification has already progressed to a certain degree.
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It is also very difficult to deliver large cells like OCs to the site of calcification and keep
them functional as our attempts to modify delivery methods failed to result in any
success. Further work in this area needs to focus on optimization of degradation of
delivery vehicle before attempting to use it for cell therapy to reverse calcification. It is
also possible that one can stop initiation of calcification of elastin as it is regulated
process but progression of calcification may occur by physical mineral deposition
(without regulation from cells) and delivery of cells may not prove successful.
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Chapter Eight
Evaluation of RANKL as a Recruiter of Native Osteoclasts to Demineralize
Calcified Elastin in vivo
Introduction
In previous chapters we established that Vitamin D3 with retinoic acid media
supplementation can differentiate BMPCs into OCs and the differentiated cells
significantly demineralize calcified elastin in vitro. Mature OCs were also able to limit
the progression of elastin calcification in vivo. Previously we have attempted to deliver
allogenic OCs to the site of calcification and it was proven ineffective at reversing
calcification. For this aim we tested whether recruitment of native OCs to the site of
calcification (by RANKL delivery) would attenuate calcification process. In a clinical
setting, it would require less surgical manipulation to recruit native cells than
transplanting cells differentiated in vitro. We hypothesized that injections of RANKL to
the site of calcification can differentiate native monocyte/macrophage cells into mature
OCs. These newly recruited cells then would be able to demineralize calcified elastin
without causing any elastin degradation. RANKL is the key factor for OC formation in
bone. Since vascular calcification resembles bone we wanted to examine if RANKL
could be effective to recruit native OCs to the site of elastin calcification and reverse the
calcification process. We also examined the effect of osteoprotegrin (OPG) on OC
recruitment. As discussed in the literature review, mature OCs are formed by RANKL
binding to RANK on the pre-osteoclasts. OPG can also bind to RANK and inhibit the
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binding of RANKL; therefore, inhibiting the formation of mature OCs. Dosages of
RANKL and OPG injections for this study were determined by previous findings of our
collaborators, who examined the effect of RANKL on osteoclastogenesis in bone [133].
To examine our hypothesis we used the subdermal calcification model of purified porcine
elastin. Once elastin calcification occurred (seven days) RANKL was delivered to the site
of calcification twice daily for seven days. We also examined the effect of OPG, which
functions as an antagonist of the effects of RANKL. Tissue explants were examined for
calcium levels, elastin degradation by desmosine content, RANKL levels, and gene
expression of Cathepsin K, an OC specific gene and Cbfa-1 and ALP, bone specific
genes.
Materials and Methods
RANKL/OPG Injections
Porcine aortic elastin was purified the same as before and implanted following the same
methods used in chapter one. The elastin was allowed to calcify for seven days. At day
seven injections began for recruitment. RANKL and OPG were delivered into each
implant twice daily at doses of 0.4 mg/kg and 0.5 mg/kg, respectively (n=4). Control
injections of saline were delivered twice daily at a volume of 0.1 ml/implant (n=4). The
animals were humanely euthanized using CO2 asphyxiation seven days later at day
fourteen.
Calcium and Desmosine Analysis
The tissue capsule was removed from the explanted elastin samples. The elastin implant
was then frozen at -80°C and lyophilized. The dried samples (~10-15 mg) were
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hydrolyzed in 6 N HCl in a boiling water bath. The hydrochloric acid was evaporated
using a continuous stream of nitrogen gas then reconstituted in 0.01 N HCl. Calcium
content was measured using atomic absorption spectrophotometry (Aanalyst 200, PerkinElmer, Norwalk, CT). The same hydrolysates were analyzed for desmosine content using
radioimmunoassay [127].
RANKL ELISA
Explanted tissue was pulverized and homogenized in RIPA extraction buffer (50nM Tris,
150 mM NaCl, 1% Triton X-100, 1% Sodium Deoxycholate, 0.1% SDS, pH 7.4) and
protein concentrations were determined using BCA assay kit (Pierce, Rockford, IL).
Protein samples were then analyzed for RANKL levels using an ELISA kit (R&D
Systems, Minneapolis, MN) following manufacturer‟s instructions.
RNA Isolation and Gene Analysis
Total RNA was isolated from tissue explants using the RNeasy Fibrous Kit (Qiagen,
Valencia, CA). Quality and quantity of RNA were evaluated on an Agilent 2100
Bioanalyzer using the RNA 6000 Nano kit (Agilent Technologies Inc., Foster City, CA).
Five hundred nanograms of total RNA was then reverse transcribed using RetroScript Kit
(Ambion, Austin, TX). The cDNA sample was further amplified using a Rotorgene 3000
thermal cycler (Corbett Research, Mortlake, NSW, Australia) and QuantiTect SYBR
Green PCR kit (Qiagen,Valencia, CA), which allowed real-time quantity detection of
PCR products. Target-specific primers were synthesized by Integrated DNA
Technologies Inc. (Coralville, IA). Minus RT and minus cDNA samples were included in
each set of samples. Each sample was normalized to the expression of ß-2 microglobulin
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(2-MG) as a housekeeping gene and compared to control samples (elastin only) using
the

2-ΔΔCT method.

Statistical Analysis
Data are reported as means ± SEM. Student‟s t-test was used to determine differences
between groups. Data are termed statistically significant when p<0.05.
Results
Calcium analysis of elastin explants showed that RANKL injections were not effective at
reversing elastin calcification. Calcium levels of the RANKL group were not
significantly lower than the saline control group (Figure 40). OPG injections also had no
effect on elastin calcification.
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Figure 40. RANKL and OPG injections had no effect on elastin calcification (n=4).
Desmosine levels were not decreased due to RANKL or OPG injections indicating no
degradation of elastin (Figure 41).
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Figure 41. Elastin is not degraded by injections of RANKL and OPG as shown by
desmosine levels (n=4).
RANKL protein levels were analyzed to better understand the results of the calcium
analysis. We wanted to determine if RANKL levels remained elevated during the
injection period. ELISA results showed the RANKL levels of the control group were not
significantly lower than that of the RANKL injection group (Figure 42) indicating that
the injections did not maintain active RANKL levels at the site of implant to be effective
at demineralization of elastin implant. On the other hand locally delivered OPG
significantly reduced RANKL levels.
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Figure 42. RANKL levels of the control are not significantly lower than that of the
RANKL injection group (n=4).
Our group has previously shown that subdermal elastin calcification expresses numerous
bone genes and proteins [26]. We wanted to examine if RANKL and OPG injections had
any effect on the gene level that may not have been expressed by calcification analysis.
We also examined Cathepsin K gene expression to determine if there was any presence of
osteoclasts at the calcification site. RANKL injections decreased the expression of bone
proteins Cbfa-1 and ALP but had no effect on reversing calcification. Cathepsin K levels
were also down regulated by RANKL injections indicating fewer osteoclasts as compared
to the elastin only control group (Figure 43). OPG injections did not exhibit decreased
Cathepsin K levels compared to the control. Even though Cbfa-1 gene expression was
not affected by OPG injections ALP was down regulated by OPG injections as compared
to control saline injections.
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Figure 43. RANKL injections down regulate Cathepsin K and bone markers compared to
saline injection controls while OPG injections only had an effect on ALP (n=4).
Discussion
Over the last decade many studies have confirmed that vascular calcification is an active
regulated process similar to that of physiologic bone mineralization and associated with
the presence of bone growth factors and matrix proteins (Shoi, 2000; Wallin, 2001). The
overall aim of this study was based on the similarities between vascular calcification and
bone. In previous chapters we have shown that BMPCs differentiated with Vitamin D3
and Retinoic acid into mature OCs can demineralize calcified elastin in vitro. They also
have the ability to limit the progression of elastin calcification in vivo if delivered before
the initiation of calcification [131]. In an attempt to mimic a clinical setting, where
patients coming to the clinic would already have calcific disease, we adapted our model
and allowed for elastin to calcify to moderate levels before the delivery of allogenic OCs
to reverse calcification. Our previous approaches of local delivery of osteoclasts were
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unsuccessful so we turned our focus toward recruitment of native cells by RANKL
delivery. We thought that delivery small protein molecule like RANKL would be easier
than delivering mature osteoclasts.
In bone, homeostasis is maintained through the RANK/RANKL/OPG system (Schoppet,
2004; Li, 2000; Boyce, 2005). RANKL (previously called OPGL) was first discovered as
a replacement for stromal cells and vitamin D3 in osteoclast cell cultures in 1998 by
Lacey and associates (Lacey, 1998; Kong, 1999; Kong, 1999). RANKL binds to RANK,
which is expressed on pre-osteoclasts. The binding is essential for all aspects of
osteoclast function such as differentiation, maturation, fusion, survival and activity. OPG
is a soluble factor produced by some cells that strongly inhibits osteoclast formation in
vitro and in vivo. OPG prevents binding of RANKL to its receptor RANK [77].
Our findings showed that both RANKL and OPG had no effect on reversing elastin
calcification that was already progressed to a moderate level. Many factors may be
responsible for this ineffectiveness. Protein analysis by ELISA also showed that RANKL
levels were not maintained at an active level to affect calcification. Thus, injections of
RANKL daily at the site were not enough to keep local RANKL levels high enough to
cause cell recruitment. It is possible that RANKL was delivered in solution and was
cleared from the area within few minutes to hours by circulatory system. More sustained
release through delivery systems such as osmotic pumps may have been more effective.
Gene analysis for bone markers showed down regulation (Cbfa-1 and ALP) in RANKL
group clearly showing some effect on osteogenesis; however, it was not enough to have
an effect on progression of calcification. It is possible that once moderate calcification
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takes place, continuous deposition of mineral occurs due to physical factors and not by
cellular pathways. Injections of OPG did significantly reduce levels of RANKL as
confirmed by ELISA clearly showing that OPG delivery did affect RANKL. However,
Cathepsin K (for osteoclast) and Cbfa-1 (for osteoblast) genes were unaffected compared
to the control (saline injections). Only the ALP gene was down-regulated in OPG groups
but it also did not inhibit the progression of calcification.
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Chapter Nine
Evaluation of osteoclasts to reverse arterial elastin-specific calcification in an
abdominal aortic injury model
Introduction
Arterial calcification resembles intra membranous bone formation with active
osteoblastic remodeling [4] [5]. Our hypothesis is that a site-specific delivery of
osteoclasts, bone resorbing cells, would tilt the balance to mineral resorption rather than
mineral deposition thus limiting vascular calcification. In previous chapters we have
shown that OCs can resorb calcium from calcified elastin in vitro and limit the
progression of calcification of pure elastin in vivo in a rat subdermal implantation model
[131]. However, attempts to reverse elastin calcification in subdermal model either by
delivering allogenic mature OCs or recruitment of native OCs by RANKL delivery were
unsuccessful.
All of this previous work was performed on purified porcine elastin to simulate vascular
medial calcification. For this study we wanted to study if OCs can be delivered to native
calcified arteries by periadeventitial route. We used an abdominal aortic injury model
which has been shown to induce medial elastin-specific calcification in rats [134]. It was
hypothesized that OCs will enter the medial layer of arteries where calcification is found
in this model and prevent progression of calcification. This is most clinically relevant
examination of our hypothesis. Abdominal aorta of rats were periadeventially treated
with calcium chloride for 15 minutes to create inflammatory conditions which is shown
to lead to progressive medical calcification. For this study, immediately after calcium
chloride injury, we placed collagen gel encapsulated with OCs periadentially to the aortic
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site. The calcification was allowed to progress for 7 days and then abdominal aortic
tissue explants were examined qualitatively and quantitatively for calcification, presence
of OCs, and for elastin integrity.
Materials and Methods
Osteoclasts were isolated using the same methods as those described previously.
Osteoclast Labeling and Collagen Gel Encapsulation
The morning of surgery mature OCs were labeled using CellTrace™ Far Red DDAO-SE
(Molecular Probes, Carlsbad, CA). Once labeled, the cells were added to a collagen
solution previously prepared with eight parts PureCol® (Advanced BioMatrix, San
Diego, CA), one part 10X Phosphate Buffered Saline (PBS) and one part 0.1 M Sodium
Hydroxide (NaOH) in a 50 mL centrifuge tube on ice. The mixture was vortexed
vigorously and pH adjusted to 6.5-7.0 with 0.5 M Hydrochloric Acid (HCl). The
cell/collagen mixture was taken up into 1 ml syringes (with tips removed for easier
implantation) with a cell concentration of 1x105cells/gel and allowed to solidify sterilely
at 37°C for ~30 minutes. Once solid, the collagen gels with encapsulated DDAO-labeled
OCs were sterilely transferred to the surgery suite for implantation.
Abdominal Aortic Injury Surgery
Adult male Sprague-Dawley rats (Harlan Laboratories, Indianapolis, IN) weighing ~250
g were placed under general anesthesia (2% isoflurane) then the infrarenal aorta (between
the renal artery and iliac bifurcation) was exposed and 0.15M CaCl2 soaked sterile cotton
gauze was applied for 15 minutes to induce calcification. The gauze was then removed
and abdominal cavity was rinsed three times with warm sterile saline. The experimental
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group (n=5) received the application of the collagen gel with the encapsulated DDAOlabeled OCs to the previously treated aorta while the control group (n=5) received none.
The abdominal cavity was closed followed by subcutaneous sutures and staples. The
animals were humanely euthanized at day seven and each injured aorta was retrieved and
processed for histological analysis, calcium and desmosine content and gene expression.
Histology
Following euthanasia, the aortic tissue was embedded in OCT (Sakura Finetek, Torrance,
CA) and frozen on dry ice. The frozen tissue was later sectioned and stained for calcium
deposits following the Dahl‟s Alizarin Red procedure. Sectioned and unstained tissue
was cover-slipped with DAPI mounting media (Molecular Probes, Carlsbad, CA) to
fluorescently image the implanted cells.
Calcium and Desmosine Analysis
The capsule was removed from the explanted samples which were then frozen at -80°C
and lyophilized. The dried samples (~10-15 mg) were hydrolyzed in 6 N HCl in a
boiling water bath. The hydrochloric acid was evaporated using a continuous stream of
nitrogen gas then reconstituted in 0.01 N HCl. Calcium content was measured using
atomic absorption spectrophotometry (Aanalyst 200, Perkin-Elmer, Norwalk, CT). The
same hydrolysates were analyzed for desmosine content using radioimmunoassay [127].

RNA Extraction and Gene Analysis
Total RNA was isolated from tissue explants using the RNeasy Fibrous Kit (Qiagen,
Valencia, CA). Quality and quantity of RNA were evaluated on an Agilent 2100
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Bioanalyzer using the RNA 6000 Nano kit (Agilent Technologies Inc., Foster City, CA).
Five hundred nanograms of total RNA was then reverse transcribed using RetroScript Kit
(Ambion, Austin, TX). The cDNA sample was further amplified using a Rotorgene 3000
thermal cycler (Corbett Research, Mortlake, NSW, Australia) and QuantiTect SYBR
Green PCR kit (Qiagen,Valencia, CA), which allows real-time quantity detection of PCR
products. Target-specific primers were synthesized by Integrated DNA Technologies Inc.
(Coralville, IA). Minus RT and minus cDNA samples were included in each set of
samples. Each sample was normalized to the expression of GAPDH as a housekeeping
gene and compared to control samples (CaCl2 only) using the 2-ΔΔCT method.
Results
Frozen sections were stained for calcium by alizarin red. The control group where only
collagen gel was used showed strong red staining for calcification in the media of the
artery while OCs group showed little to no staining for calcium. (Figure 44) To test
whether osteoclasts that were delivered stayed in place we used fluorescent imaging. OCs
were tagged with DDAO that stains them red. In OCs group we found more red staining
for cells as compared to control in the adventitia of the aorta. When DAPI counter stain
was used for the same section the red staining corresponded with clumped multinuclear
cells. This data suggested that delivered OCs survived and were present at the site at the
time of explanation. However, the cells were only seen in the adventitial region of the
aorta and not in the media. Calcification was mainly observed in the medial region of the
aorta. It seems that OCs did not migrate through to the medial layer where the
calcification was located.
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Figure 44. Histological analysis shows the calcification (red of Alizarin Red staining) is
isolated to the medial layer and although OCs were successfully delivered, they are only
in the adventitial layer and did not migrate to the site of calcification.
We also tested OCs presence by quantitative cathepsin gene activity by RT-PCR (known
marker for OCs). Gene analysis confirmed that that there was four- fold increase in
Cathepsin K gene expression in OCs group as compared to controls clearly showing that
OCs were present and were expressing CatK. (Figure 45).
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Figure 45. Gene analysis confirms the successful delivery of OCs (n=4).

Quantitative calcium analysis (Figure 46) contradicted the histological findings because
there was no significant reduction in calcification by the delivery of OCs. In this study
quantitative calcium data showed far lower calcium levels in both groups as compared
our previously published results [134].
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Figure 46. Locally delivered OCs did not have an effect on reducing calcification (n=5).
We also tested if osteoclast delivery would increase elastin degradation in the arteries as
OCs are known to secrete ECM degrading enzymes. Desmosine analysis confirmed that
there was no significant elastin degradation by the delivery of the OCs (Figure 47).

1800
1600

pm Des/ mg Pro

1400
1200
1000
800
600
400
200
0
Ctrl

OC

115

Figure 47. Elastin integrity is maintained in the presence of OCs (n=5).
Discussion
Medial elastin-specific calcification is observed in many different diseases such as
Monckenberg‟s sclerosis, ageing, diabetes and end-stage renal failure. Previous work by
our research group has shown that the application of CaCl2 to the abdominal aorta of a rat
results in medial elastin-associated calcification [134]. Gene analysis of this previous
work showed that this model expressed osteogenic genes. Given the similarities between
vascular calcification and bone, we attempted to reverse medial calcification with a sitespecific delivery of OCs. Native arteries do not express any resemblance to bone but
during diseased states such as Monckeberg‟s sclerosis, bone matrix proteins are
expressed [24].
Attempting to reverse vascular calcification using cell therapy is a novel concept. We
were able to successfully deliver the OCs to the injured tissue as confirmed by histology
and gene expression but the cells only migrated to the adventitial layer of the artery
which was also observed by histological analysis. Successful delivery of the OCs was
not effective at demineralizing the medial vascular calcification because calcium analysis
did not show any reduction of calcification in the presence of OCs. Also the calcification
was isolated to the medial layer of the aorta as confirmed by Alizarin Red staining and
the OCs were only in the adventitial layer and did not penetrate to the medial layer to
reverse calcification. It is also important to note that our studies did not induce
calcification to the level of that previously shown by our group. Previous studies were
able to induce calcification using CaCl2 to ~15ug Ca/mg dry tissue, while our study only
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calcified to 1.5ug Ca/mg dry tissue. The reason for this lower calcification is unknown. It
is possible that because we did not find any significant calcification in control group, we
were unable to show lower calcification in the osteoclast group. Only one of control
group vessel showed significant calcified area (by alizarin red) while none of the
osteoclast group showed any alizarin staining. This makes us speculate that study was
successful but due to insufficient numbers of animals no conclusions could be drawn
whether calcification was reduced or not. This warrants repetition of the study.
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Chapter Ten
Conclusions and Recommendations
Conclusions
The basis of this dissertation was the similarities between bone mineralization and
vascular calcification. We hypothesized that a site-specific delivery of osteoclasts, the
only bone resorbing cells, would be able to limit and reverse vascular elastin
calcification. For this we determined the most effective method of media supplementation
for OC differentiation from BMPCs. These cells were effective at forming resorption pits
on hydroxyapatite discs and demineralize calcified elastin. Next, OCs were cultured to
maturity using the chosen method of Vitamin D3 with retinoic acid and were also able to
form resorption pits on hydroxyapatite discs and demineralize calcified elastin. In vivo
studies then confirmed that OCs were able to limit the progression of elastin calcification
using a rat subdermal model for accelerated elastin calcification.
Using the same model we then attempted to reverse elastin calcification. Elastin was
allowed to calcify before the cell therapy treatment was applied. Three different delivery
methods were used for this attempt at cell therapy. First, cells were suspended in saline
and injected directly into the elastin implant. This approach had no effect on reducing
calcification probably because the cells did not remain at the implant site. Next, cells
were encapsulated into a collagen gel for delivery to the implant site. Collagen did not
serve as the ideal delivery vehicle because it degraded too quickly and did not keep the
cells at the implant site. Lastly, collagen/alginate beads were used as the delivery vehicle
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for OCs. The beads did keep the cells localized but did not degrade during the in vivo
study for the OCs to have an effect on calcification.
We also attempted to recruit native OCs to the site of calcification using RANKL.
Injections of RANKL did not effectively recruit native OCs in vivo to reduce
calcification.
The second animal model used was a circulatory more clinically relevant model. We
attempted to create medial vascular calcification and deliver OCs to the injured tissue to
reverse calcification. OCs were successfully delivered to the vascular tissue but only to
the adventitial layer and not the medial layer where the calcification was located. Our
aortic tissue also did not calcify to extent of that observed by previous studies.
Recommendations
Many studies have shown the numerous similarities between vascular calcification and
bone mineralization and several review articles have contemplated OCs being the key to
reverse vascular calcification. Given the success of our in vitro studies, it seems the in
vivo studies would have similar results. Reversal of calcification is still possible but two
factors need to be optimized. The delivery vehicle and the duration of the cell therapy
treatment should be ideal.
The delivery vehicle should be optimized first by performing an extensive literature
review to identify a few possible options for a polymer delivery vehicle. The polymers
should then undergo an in vivo time-course degradation study. Cells could be
fluorescently labeled and incorporated into the polymers and degradation could be
visualized using the same Lumazone imaging technology that was used for this
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dissertation. Once an ideal polymer is identified, the duration of the cell therapy
treatment should be optimized.
In vivo studies involve many different factors that are not present in vitro and OCs may
need to more time to reverse elastin calcification. A time-course study would be needed
to determine the ideal duration of the cell therapy treatment to ensure that OCs could
have a chance to reverse calcification.
The circulatory model study would need to be repeated to achieve the calcification levels
observed by others.
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